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Background: There are few data for treatment-related outcomes in patients with XDR 
tuberculosis in settings with high HIV prevalence.  
Methods: We reviewed the case records of 227 consecutively diagnosed South-African 
patients with XDR-TB between August 2002 and February 2008 at four designated 
provincial treatment facilities.  Mortality and conversion were stratified by HIV status.  
Furthermore, the records of 115 patients, from three out of the four centres, were 
retrospectively analysed for adverse drug reactions (ADRs), which were graded for severity 
(severe= therapy stopped, life threatening or death).  
Results:  Of 227 patients studied, 195 XDR-TB patients were included in the study and 174 
(82 HIV-infected) received treatment. 36% (62/174) died during follow up. The overall 
culture conversion rate was 19% (33/174) and 70% of patients converted within 6 months. 
Mortality rates in HIV-infected patients were not significantly different from uninfected 
patients [41.5% (34/82) vs. 30.4% (28/92) (p=0.13)]. Treatment with moxifloxacin, prior 
culture-proven MDR-TB, and increasing number of drugs used were independent predictors 
of death.  HIV-infected patients treated with HAART had lower mortality (hazard ratio = 
0.31, 95% CI 0.15-0.61, p=0.01). 58% (67/115) patients experienced 161 ADR’s.  The 
offending drug was discontinued in 19/67(28%) of patients, reactions were life-threatening 
in 2/67(3.0%) and 6/67(9.0%) died.  Patients with severe ADRs were less likely to culture-















(p=0.003). Only culture conversion and a history of MDR-TB were independent risk factors 
for mortality in those with severe ADRs compared to those wild mild, moderate or no 
ADRs. Death from an ADR was commoner in HIV-infected patients [5/6(83.3%) vs. 
1/6(16.6%), p=0.01)].  
Conclusions: In South Africa a significant proportion of XDR-TB patients remain HIV-
unrelated, and prognosis, regardless of HIV status, poor. Nevertheless, survival in HIV-
infected patients is better than previously reported, and treatment with HAART improves 
outcomes. The frequency of ADR’s with XDR-TB treatment regimens is high, often severe, 
and negatively impacts on culture conversion outcomes. These data have implications for 
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1.1  Introduction: 
Here I will review the literature about drug resistant tuberculosis (DR-TB) globally, 
in the African continent, and more specifically in the South- African context. 
Although the work presented here is specifically about extensively drug-resistant TB 
(XDR-TB), I will also discuss multi drug-resistant TB (MDR-TB). XDR-TB is mostly 
acquired as a result of failed MDR-TB treatment making an understanding of MDR-
TB necessary.  
 
1.2      Global history and Epidemiology of MDR and XDR-TB 
1.2.1 Background 
Despite its decline in Europe and North America, Mycobacterium tuberculosis (MTB) 
continues to be a major global killer and the most common cause of chronic 
pulmonary disability in the 21st century. There are  10 million cases reported 
annually worldwide (Corbett et al., 2006) and MTB is the leading cause of death in 
South Africa (statistics South Africa, 2009). Over the last two decades resistance to 















and extensively-drug resistant (XDR-TB). MDR-TB has been defined as resistance to 
isoniazid and rifampicin and XDR-TB resistance to rifampicin, isoniazid, one of the 
fluoroquinolones, and at least one of the second-line injectable agents (i.e. 
kanamycin, amikacin or capreomycin) (CDC, 2006). In 2008 there were 
approximately 500 000 cases of MDR-TB globally and more alarmingly, about 5% to 
10% of MDR-TB cases are thought to be XDR-TB. MDR-TB and XDR-TB threatens to 
destabilise TB control in several regions of the world including Africa, Eastern 
Europe, Russia, central Asia, India and China. This has resulted in a dire situation in 
South Africa, where the human immunodeficiency virus (HIV) co-infection is fuelling 
the spread of the epidemic.  
 
 1.2.2 Development of drug-resistant tuberculosis 
The history of drug resistant tuberculosis dates back to soon after the first drug for 
treating TB was made available. Streptomycin was introduced in 1944, and in 1947 
Pyle et al. described resistance to streptomycin (Pyle, 1947). The hypothesis of 
naturally existing resistant variants was confirmed in 1952. Lederberg and 
Lederberg showed that resistance of the tubercle bacillus to antimicrobial agents 
was not caused by the drug but a process where resistant variants, which pre-exist, 
were effectively selected for survival (Lederberg and Lederberg, 1942).  About the 
same time it was shown that resistance to isoniazid occurred shortly after its 
introduction as an anti-TB drug.  Bacillary population size and its ability to multiply 
were identified as two important pre-requisites for the emergence of bacterial 















developed, descriptions of individual resistance and cross-resistance between 
different drug classes was described (Canetti, 1962, Middlebrook, 1954) (Mitchison, 
1984). Although all the anti-tuberculosis drugs cause resistance, some confer 
resistance quicker than others, by selection of pre-existing resistant variants. 
                                                                                                                                                                                                                                                                                                                                                       
Canetti (1965) found that the ability of a single anti-tuberculosis drug to enhance 
the selection of resistance depended on a certain drug concentration in vivo, and 
the drugs ability to get rid of drug susceptible portions of the microbial population 
(Canetti, 1962, Canetti, 1965). Later David (1970) showed that the rate of 
spontaneously resistant variants in a sample of wild type mycobacterium should be 
3.5 x 10-6 for isoniazid, 3.8 x 10-6 for streptomycin, 3.1 x 10-8 for rifampicin, and 0.5 x 
10-4 for ethambutol. Based on these frequencies, the probability of a naturally 
occurring bacillus resistant to isoniazid and rifampicin is approximately 1 in 10 
bacilli (David, 1970.) This work clearly demonstrated that in order for TB treatment 
to be successful, several anti-TB drugs, especially in the early phase of treatment 
when the bacillary load is at its highest and contains large enough numbers of 
naturally occurring drug-resistant variants, are required. Because of this, two 
phases of TB treatment were described: the initial phase, when numbers of 
organisms are high, followed by the continuation phase, when smaller numbers of 
bacilli need a prolonged chemotherapeutic course to ensure all bacilli are killed. 


















 1.2.3 Drug resistant tuberculosis in America 
A study conducted in the United States in 1991 (CAUTHEN et al., 1994) on all 
culture positive TB isolates with drug susceptibility testing (DST) results found 
resistance to one or more drugs in 14.2% of cases and resistance to isoniazid and / 
or rifampicin was 9.5%. This is substantially higher than published estimates in 
South Africa in 2002 (MRC, 2004). Another study done in New York showed that 
patients with MDR-TB were as likely to be foreign born as USA born. Responding to 
this growing public health crisis, the national MDR-TB task force recommended in 
1992 that DST be performed on initial MTB isolates on all TB patients. This, in 
addition to increased drug resistant surveillance, meant that from 1993 - 2000   the 
number of MDR-TB cases in the Unites states declined from 485 to 141, mainly in 
New York (CDC, 2001) (Shah and al., 2008).                                                                                                                                                                                                                         
















1.2.4 Emergence of drug-resistant TB in other countries 
A review of 63 surveys of resistance to anti-tuberculosis drugs was carried out 
between 1985 and 1994 (Cohn et al., 1997). Isolates from new TB cases showed 
10.6% of patients were resistant to isoniazid, 9% to streptomycin, 2.4% to 
rifampicin and 1.8% to ethambutol. Rates for retreatment cases were much higher 
and the median rate of resistance to isoniazid was 10.6%, to streptomycin 4.9%, to 
rifampicin 2.4%, and to ethambutol 1.8%. The rates of MDR-TB among new cases 
ranged from 0 to 10.8% (median, 0.5%) and among retreatment cases: Nepal 
48.0%; Gujarat, India 33.8 %; New York City 30.1%; Bolivia 15.3% and Korea 4.5%. 
As a result, the World Health Organisation (WHO) and United States Centers of 
Disease Control (US CDC) started a global project on anti-tuberculosis drug resistant 
surveillance in 1994. By 2000 two global surveys had been completed, the first from 
1994 - 1996 (Pablos-Mendez et al., 1998) and the second from 1996 - 1999 (Espinal 
et al., 2001). Seventy two regions were included in at least one of the surveys and 
isolates from about 118 000 patients were tested. The geographic area covered 
33% of the world’s population. The results showed that drug resistant TB was 
present in all areas surveyed although in small proportions (Cegielski et al., 2002). 
In the second survey, the median prevalence of MDR was 1%, with a range of 0-
14.1%. Seven geographic area had high levels of MDR-TB >5% among new cases; 
four of these sites (Estonia, Latvia, and Ivanovo and Tomsk Oblasts of the Russian 
Federation) were in the former Soviet Union. A report from 2002, (Dye et al., 2002), 
was the first comprehensive incidence estimates of the MDR-TB burden in 136 
countries making up 97% of the world’s population. Dye et al. estimated there were 
273 000 MDR-TB cases worldwide which comprised of 3.2% of all TB cases (Dye et 
















In the fourth global report on anti-TB drug resistance (WHO/IUATLD, 2008) data on 
the extent of drug-resistant TB between 2002 and 2007 was reviewed. This report 
includes data for drug susceptibility testing (DST) of 90 726 patients from 83 
countries (Wright et al., 2009). The median prevalence of MDR-TB in new cases was 
1.6% (IQR 0.6-3.9) ranging from 0% in eight countries with low TB prevalence to 
19.4% in Moldovia and 22.3% in Baku, Azerbaijan. The median prevalence of MDR-
TB in previously treated TB cases was 11.7% (IQR 4.9-20.9) (Wright et al., 2009). 
Among the 17 settings reporting a prevalence of MDR-TB >25% in retreatment 
cases, nine were in former Soviet Union countries (WHO and IUATLD, 2008). At 
least one country in all of the six WHO regions reported a prevalence of 
approximately 3% MDR or XDR-TB cases among newly diagnosed TB cases (WHO 
and IUATLD, 2008, Chiang et al., 2010).  
 
From November 2004 to November 2005 the global Supranational Reference 
laboratories (SRL) Network requested all Mycobacterium tuberculosis isolates that 
had undergone testing for first and second-line drug susceptibility testing between 
2000 and 2004 to be reviewed. The study found that 20% of isolates met MDR-TB 
definitions and 2% were classified as XDR-TB. Population-based assessment showed 
that 4% of the cases were from the USA, 15% from South Korea and 19% from 
Latvia. In 2010, 58 countries from all the continents had reported at least one case 
of XDR-TB. Altogether 963 cases were notified globally compared with 772 cases 
from 28 countries in 2007. It is believed that many XDR-TB cases are never 















many patients die before they are recognised as MDR or XDR-TB (M/XDR) (Shah, 
2007).  
 
In 2009 there were just over 30 000 MDR-TB cases reported globally which is just 
7% of the estimated 440 000 cases (range, 390 000 - 510 000). This shows the 
limited availability of DST in many countries because of a lack of laboratory 
capacity. Twenty-seven high burden countries are responsible for 86% of all such 
cases. The four countries with the largest numbers of estimated MDR-TB cases 
were China, who reported 100 000 cases (range, 79 000 - 120 000), India with 99 
000 (range 79000 – 120 000), the Russian Federation with 38 000 (range, 30 000 - 
45 000) and South Africa with 13 000 (range 10 000 - 16 000). This suggests that 
overall, the numbers of patients diagnosed with MDR-TB and started on treatment 
will almost double in 2010 and 2011 compared with 2009. Although countries are 
taking steps to improve their surveillance systems, most available data is from “ad 
hoc” designed studi s(Sotgiu et al., 2009);Migliori, 2008 #1436;Chiang, 2010 
#1435}, which do not allow for scientific clarification. 
 
















 1.2.5 Emergence of drug-resistant tuberculosis in Africa  
Although data from Africa are, in general, scanty, due to weakness of the laboratory 
infrastructure and difficulties in performing DST, six countries reported drug 
resistance data to WHO for the fourth global report (WHO and IUATLD, 2008). It 
was estimated at this time that over 60 000 drug-resistant cases are probably 
occurring in Africa which accounts for 30% of the global burden; half of these 14% 
new cases (Chiang et al., 2010). Thirty-four countries in Africa reported MDR-TB 
cases and eight XDR-TB cases (WHO, 2010).  Of the nine countries that were 
estimated to have over 5 000 incident MDR-TB cases, three of these countries, 
Ethiopia, Nigeria and Sudan, were from Africa. However, as only 50% of the 
population is represented in WHO/IUATLD studies, the true extent of drug-resistant 
tuberculosis is unknown and likely to be underestimated (Schaaf et al., 2009). A few 
MDR-TB hotspots (i.e. MDR-TB > 3% of TB cases) have been reported in Africa: 
these include Mozambique, Cote d’Ivoire and more recently Rwanda and 
Democratic Republic of Congo(Schaaf et al., 2009)}. Nine African countries rate 
among the 27 high burden MDR-TB countries: South Africa (4th), Nigeria (9th), 
Democratic republic of Congo (13th), Ethiopia (16th), Kenya (20th), Mozambique 
(21st), Zimbabwe, (23rd), Cote d’Ivoire (25th) and Sudan (26th) (Schaaf et al., 2009). 
Those defending WHO data argue that national TB programmes are working well, 
and due to the later introduction of rifampicin to African countries, there has been 
















It has also been suggested, that the rifampicin argument (as mentioned above) may 
also be invalid. Mozambique started using rifampicin about 10 years after South 
Africa and yet their MDR-TB rate is already higher than South Africa’s. The MDR- TB 
rate in Mozambique, which introduced rifampicin at the same time as Gambia, is 10 
times higher than that in Gambia. It can be argued that African countries that are 
able to carry out drug resistant surveys are more likely to have well-functioning 
national TB programs, laboratory structure, and transport networks and therefore 
lower rates of MDR-TB than those countries without these resources. 
 
The low MDR-TB rates among TB cases in Africa compared with that in regions such 
as Eastern Europe and Central Asia could be due to outdated studies or surveys in 
which the scientific rigour is questionable or coverage is not nationwide. 
Nevertheless, given that African countries have the highest incidence rate of TB in 
the world, even at low proportions of drug resistance the caseload of MDR-TB 
patients is very high. As a result, the rates of MDR-TB cases arising per 100 000 
population in some southern African countries are five to six times higher than 
those of China and India. Latest estimates of WHO put the number of MDR-TB cases 
emerging in 2008 in Africa at 69 000 (53 000 - 110 000) (WHO, 2010). Because of 
the factors mentioned previously, these estimated numbers of MDR-TB cases are 
based on mathematical modelling rather than empirical studies. Laboratory 
surveillance for MDR-TB and XDR-TB should be strengthened and expanded across 
the region, particularly in countries with large populations where studies have 















Figure 1.1 African countries with a known MDR-TB rate. 
Map 1: Represents data from the 3rd global WhO/IUATLD report -2004 (WHO and IUATLD, 
2004). 
Map 2: Represents data from the 4th WHO/IUATLD global report, 2008. (WHO and IUATLD, 
2008).   
Map 3: Based on a formula developed by Zignol et al.(Zignol et al., 2006), to estimate the 
MDR-TB rate in countries where  a survey has never been conducted. 
 
             1.2.6  A brief look at M/XDR-TB in sub saharan Africa 
The number of TB cases in sub-saharan Africa has risen sharply i  the past 10 years 
due largely to the HIV epidemic (WHO and IUATLD, 2008) (Raviglione and IM, 2007). 
WHO estimates that between 1990 and 2005 the incidence of tuberculosis doubled 
from 149 to 343/100 000 population. However, despite the high prevalence of 
HIV/tuberculosis co-infection the second global resistance survey measured MDR 
rates of only 0.8-2.6% in the sub saharan African region (WHO and IUATLD, 2004).  
 
 1.2.7 Development of drug-resistant tuberculosis in South Africa 
The first cases of MDR-TB in South Africa were diagnosed in 1985 in Gauteng 
province and shortly thereafter in the Western Cape. A retrospective analysis of 
MDR-TB patients notes and their DST results revealed that XDR-TB cases were to be 
found as far back as 1992. In 2000 a pilot project with standardised treatment 
regimens for MDR-TB was implemented in all provinces by the Department of 















the MDR-TB programme was officially incorporated into the National TB control 
programme. 
 
South Africa is ranked as the fourth highest drug-resistant TB high burden country 
in the world, behind countries with much larger populations such as China, India 
and the Russian Federation. Almost 7 000 cases of M/XDR-TB were notified in 2008, 
most coming from KwaZulu-Natal and the Western Cape.  
 
The true impact of drug-resistant TB in sub- saharan Africa became known with a 
report from a rural hospital in Tugela Ferry, KwaZulu-Natal, South Africa, (Gandhi et 
al., 2006a). The study showed that of the 1539 people tested for tuberculosis (Jan 
2005, to March 2006), 542 had a culture positive for M. tuberculosis and of these 53 
had XDR-TB.  Median time of death from sputum collection was 16 days (range 2 - 
210 days) for 52 of 53 patients who died. Even more alarming was that 26(55%) of 
the patients had no history of previous TB although 67% had a recent hospital 
admission before their TB diagnosis. These two points suggest nosocomial 
transmission in this outbreak of XDR-TB. It is estimated that 1.8% (range 1.5-2.3) of 
all new cases of TB in South Africa are MDR-TB cases and 6.7% (5.5-8.1) of 
retreatment cases. It is expected that in South Africa 7 301 MDR-TB patients will be 
treated in 2010 and 8 642 in 2011 (WHO, 2010)  demonstrating continued growth 


















































932 932 171 171 797 772 135 135 1006 847 158 135 
Free State 
 
158 158 10 7 265 233 7 7 216 148 7 6 
Gauteng 
 
497 497 45 45 601 414 40 40 808 512 29 25 
KwaZulu 
Natal 
788 788 170 170 1061 1039 165 163 969 927 183 177 
Limpopo 
 
71 71 2 2 104 104 0 0 90 88 3 3 
Mpumala-
nga 
148 148 0 0 272 272 3 3 198 198 5 5 
Northern 
Cape 
145 145 11 11 148 148 8 8 70 253 14 13 
North 
West 
156 156 4 4 159 159 1 1 175 175 9 9 
Western 
Cape 
862 439 81 64 1145 890 59 34 1201 995 86 58 
South 
Africa 
3 757 3334 494 474 4552 4031 418 391 4933 4143 494 431 
 
Reg = Registered, Rx=treatment 
Table 1.1     MDR-TB and XDR-TB cases, registered, in South Africa compared to those in 
whom treatment was initiated, per province, 2007-2009 (NTP) 
 
 
Table 1.1 shows the large gap between the numbers of MDRs diagnosed registered 
and started on treatment, per province. In 2008 the National TB programme (NTP) 
did not start treatment in nearly 35% of all diagnosed MDR-TB patients and 32% of 
all diagnosed XDR-TB patients. Initiation of treatment depended on the prevalence 
of drug-resistance in that particular province as well as accessibility and efficiency 
















 1.2.8 Molecular Epidemiology 
“The ability to discern the molecular “fingerprint” (GENO-type) of M. tuberculosis 
isolates has revolutionised our understanding of the transmission of tuberculosis” 
(Barnes and Cave, 2003). Genotyping of isolates from patients is useful in several 
situations: 
1. About 3% of patients, from whom M. tuberculosis is apparently isolated in a 
clinical laboratory, do not have tuberculosis; the positive cultures are due to 
cross contamination. When clinical findings are not suggestive of 
tuberculosis although M. tuberculosis has been isolated, concurrent 
genotyping could suggest cross contamination and lead to anti-tuberculosis 
drugs being stopped. 
2. Genotyping allows for isolates with different drug susceptibility which can 
be useful in cases where (a) the original organism developed drug resistance 
during or after anti-tuberculosis therapy, (b) the patient was re-infected 
with a different strain or (c) cross-contamination is suspected. Genotyping 
isolates from the patient and others done at the same time can look at all 
the possibilities. If the first organism developed resistance, the cause could 
be non adherence to therapy, lower concentrations of drugs used for 
treating the TB, as a result of malabsorbtion of the drugs or by drug 
interactions. If the cause is re-infection health authorities should attempt to 
















3. Genotyping can be used to identify whether a patient has been re-infected 
or has relapsed, using isolates from previous and present episodes. If the 
patient has relapsed, the susceptibility of the original isolate can be used to 
guide treatment and reasons for treatment failure evaluated. If the patient 
has been re-infected the source case should be found. It is important to 
distinguish between relapse and re-infection to be able to define treatment 
failure. 
4. Genotypic methods plus epidemiologic factors can help determine whether 
an outbreak has occurred or whether there is a coincidental occurrence of a 
large number of cases. There is huge variability in the genotypes of M. 
tuberculosis isolates with epidemiologically unrelated tuberculosis, but 
identical in cases that have been infected by a common source (isolates with 
identical or closely related genotypes are known as clusters). 
 
Spoligotyping of XDR-TB isolates collected retrospectively in four provinces 
identified 17 strains belonging to seven lineages during the period June 2005 to 
December 2006 (Mlambo, 2008). The genetic diversity and wide geographical area 
that these strains came from suggest that in 63% to 75% of cases, XDR-TB had been 
acquired. This study further showed that XDR-TB was mostly associated with the 
















1.3    Clinical features of M/XDR-TB 
The clinical presentation of MDR-TB and XDR-TB is similar to that of drug-
susceptible TB. Risk factors are described in section 1.3.1 below, but it must be 
remembered that in up to half of, the diagnosed cases of drug-resistant TB, there 
may be no risk factors. In HIV-infected patients, the clinical and radiological picture 
may be atypical, with a more rapid disease progression especially in the setting of 
nosocomial transmission with virulent strains.(Gandhi et al., 2006a)  
 
1.3.1 Risk factors 
M/XDR-TB may be linked to previous TB treatment.   The prevalence of drug 
resistance among previously treated TB cases was much higher than that among 
new TB cases (WHO, 2008, WHO, 2000, Chiang et al., 2010). Six common treatment 
errors have been identified: (1) addition of a single drug to a failing regimen, (2) an 
inadequate primary regimen, (3) failure to recognize initial or acquired resistance, 
(4) failure to recognise and deal with non-adherence, and (5) failure to provide 
directly observed treatment (Spradling and Ridzon, 2003). It is reported that the 
probability of any resistance in previously treated patients is over four-fold higher, 
and that of MDR-TB over ten-fold higher, then for untreated patients (Espinal et al., 

















Risk factor  
 
Comments  
Failure of retreatment regimen 
(Regimen 2)/ chronic TB patients  
Chronic TB patients are defined as patients who are sputum 
positive at the end of the intensive phase and on completion of re-
treatment regimen. These patients have the highest MDR-TB rates, 
often greater than 80%.  
Exposure to a confirmed MDR-TB 
patient  
Most studies have shown that close contacts of MDR-TB patients 
have very high rates of MDR-TB. This includes children, who should 
be started on MDR-TB therapy empirically until proven not to have 
MDR-TB. This could also include hospitalized TB patients in settings 
where MDR-TB is diagnosed.   
 
Failure of treatment regimen for new 
patients (Regimen 1)  
Failures of Regimen 1 or Regimen 3 are adult or paediatric 
patients, respectively, who remain positive at the end of the 
intensive phase or become sputum smear or culture positive 5 
months or later during the course of treatment. 
Relapse and default  Erratic drug intake or early relapse may point to possible MDR-TB. 
Relapses within the first six months post-treatment may have 
similar MDR-TB rates as failures. Repeated interruption of 
treatment can also result in selection for resistant mutants. 
Use of drugs that compete with or 
alter the metabolism of TB drugs, 
resulting in reduced serum levels 
 
Antifungal agents in the azole family interfere with rifamycins will 
lower azole levels. In addition ketoconazole can lower rifampicin 
levels by 40%-50%;  protease inhibitors  (Lopinivar/ritonavir 
(Kaletra) can affect the absorption of other drugs by the body. 
Co-morbid conditions associated 
with malabsorption or rapid transit 
diarrhoea  
 
Malabsorbtion may result in selective low serum drug levels and 
may occur in either HIV negative or positive patients. 
HIV Numerous MDR-TB outbreaks have been documented in HIV+ 
individuals as a result of the depressed immune system and high 
susceptibility to infection. 
    
(Adapted from: World Health Organization. Guidelines for the Programmatic Management of drug-
resistant Tuberculosis (WHO/HTM/TB/2005.361), World Health Organization: Geneva, Switzerland, 
2008). 
Table 1.2     Risk factors for MDR-TB (Health, 2010)   
 
Other risk factors not included in the above table include:  
 Immigration from high prevalence countries can increase the risk of 
being infected by a resistant strain, affecting not only foreign born 















 There is also strong evidence that TB is more common among 
children living in a household affected by TB (Chiang et al., 2010, 
WHO, 2000). 
  Alcohol, substance abuse and other socio-economic factors such as 
homelessness, malnourishment and poor living conditions, or have a 
higher defaulter rate have been shown to have a higher prevalence 
of MDR-TB.  
 
 
1.3.2 HIV co-infection 
In 2007 it was estimated that of the 9.27 million people with new TB infections,  
1.37 million of them were co-infected with HIV 14.8%, and that some 456 000  of 
these co-infected patients died. Of serious concern is the fact that in some 
countries in sub-saharan Africa, the TB/HIV co-infection rates are between 50% and 
80% (WHO, 2009, Nunn et al., 2007).  South Africa and Zimbabwe have the highest 
incidence, mortality, and HIV/TB co-infection rates among the 22 high-burden 
countries (Table1.3). In a systematic Review conducted by Suchindran et al. 
explored the question of whether HIV infection was a risk factor for multi-drug 
resistant tuberculosis. While they could not find an overall association between 
MDR-TB and HIV, or acquired MDR-TB and HIV, there is a possible association with 
primary MDR-TB and HIV (Suchindran et al., 2009). There is little data from Africa 















of the XDR-TB patients were HIV-infected and the median time to death was 16 
days (Gandhi et al., 2009). 
 
22 countries with the highest-burden of TB
 
Country Incidence of TB 






HIV prevalence in 
incident TB cases, 
in %
 
MDR in new 
cases, in %
@ 
South Africa 948 230 73 1.8 
Zimbabwe 782 365 69 1.9 
Cambodia 495 89 7.8 <0.0 
Mozambique 431 127 47 3.5 
DR Congo 392 82 5.9 2.3 
Kenya 353 65 48 1.9 
Ethiopia 378 92 19 1.6 
Uganda 330 93 39 0.5 
UR Tanzania 297 78 47 1.1 
Nigeria 311 93 27 1.8 
Philippines 290 41 0.3 4.0 
Indonesia 228 39 3.0 2.0 
Bangladesh 223 45 0 3.5 
Pakistan 181 29 2.1 3.2 
Vietnam 171 24 8.1 2.7 
Myanmar 171 13 11 4.0 
India 168 28 5.3 .8 
Afghanistan 168 30 >0.05 3.3 
Thailand 142 21 17 1.7 
Russ. federation 110 18 16 13 
















22 countries with the highest-burden of TB
 
Country Incidence of TB 






HIV prevalence in 
incident TB cases, 
in %
 
MDR in new 
cases, in %
@ 
South Africa 948 230 73 1.8 
Zimbabwe 782 365 69 1.9 
Cambodia 495 89 7.8 <0.0 
Mozambique 431 127 47 3.5 
DR Congo 392 82 5.9 2.3 
Kenya 353 65 48 1.9 
Ethiopia 378 92 19 1.6 
Uganda 330 93 39 0.5 
UR Tanzania 297 78 47 1.1 
Nigeria 311 93 27 1.8 
Philippines 290 41 0.3 4.0 
Indonesia 228 39 3.0 2.0 
Bangladesh 223 45 0 3.5 
Pakistan 181 29 2.1 3.2 
Vietnam 171 24 8.1 2.7 
Myanmar 171 13 11 4.0 
India 168 28 5.3 .8 
Afghanistan 168 30 >0.05 3.3 
Thailand 142 21 17 1.7 
Russ. federation 110 18 16 13 
China 98 15 1.9 5.0 
 @
MDR, multidrug resistance to (at least) isoniazid and rifampicin
 
Table 1.3     World Health Organisation estimates of the incidence and mortality of 
all types of tuberculosis per 100 000 population, the prevalence of HIV incident TB 















HIV-infected persons with latent M. tuberculosis infection are at a much 
higher risk of developing tuberculosis and of those that do get active 
disease; the prognosis is dire (Nunn et al., 2007). Tuberculosis cases among 
HIV co-infected people is also difficult to diagnose with conventional 
diagnostics, and patients could be started on ineffective treatment 
regimens, resulting in an increase in morbidity and mortality in co-infected 
individuals (Jassal and Bishai, 2009). DR-TB treatment is the same for HIV-
infected and uninfected patients but patient management can be more 
complicated with more adverse drug reactions being experienced in co-
infected patients.  Mortality is also high during treatment especially in a 
patient with the advanced stages of immunodeficiency. Patients already on 
antiretroviral treatment when MDR- or XDR-TB is diagnosed should 
immediately be started on appropriate DR-TB treatment.   If the patient 
presents with DR-TB before commencing ART the initiation should be fast 
tracked as soon the DR-TB treatment is tolerated (Figure 1.4) (Health, 2010). 
Does HAART in HIV-infected XDR-TB patients make a difference in 
outcomes? If so when should the HAART be initiated in relationship to the 
initiation of the XDR-TB treatment? What about side effects of the ARVs. 


















Figure 1.2    Flow chart for anti-retroviral therapy in adult patients with drug-resistant 
tuberculosis  
HIV positive patient diagnosed with DR-TB
Patient not on ART at time 
of diagnosis
Patient on ART at time of 
diagnosis 
Start ART irrespective of CD4 cell 
count once DR-TB treatment is 
tolerated preferably within first 
month of treatment. 
First-line therapy: 
1. Tenofovir 300 mg daily 
and
2. Lamivudine 150mg every 12 
hours and
3. Efavirenz 600mg at night 
or 
Nevirapine 200 mg every 12 hours
Start DR-TB treatment 
immediately 
Continue ART throughout DR-TB 
treatment 
First-line therapy: 
1. Tenofovir 300 mg daily and 
2. Lamivudine 150mg every 12 
hours 
and 
3. Efavirenz 600mg at night 
or 




 1.3.3 Transmission dynamics (clinical aspects) 
MDR-TB cases are generated by transmission in congregate settings and these cases 
are being generated faster than emerging M/XDR-TB treatment programmes can 
cure them. It is estimated that under 10% of MDR-TB cases are being treated 















transmission (WHO, 2010). It is also thought that transmission is mainly from 
unknown or inadequately treated persons with MDR and XDR-TB thus fuelling the 
global DR-TB epidemic especially where HIV rates are high. Once mutant organisms 
are selected by poor chemotherapy, the airborne spread needs to be curbed and 
the most effective way to do this is by prompt diagnosis and effective treatment. 
Adding to this are the limitations of Infection control practises in health care 
institutions. Health care facilities have both patients and health care workers 
(HCW’s) who are HIV infected and those with DR-TB who in turn can be infected or 
re-infected (Joshi et al., 2006). The lack of rapid diagnostics results in transmission 
from unsuspected cases in the community, clinics, hospitals, prisons and other 
congregate settings (WHO, 2010).  
 
Most TB facility guidelines concentrate on the known or suspected cases already on 
treatment but it has been known for some time that the bigger risk is from 
unsuspected, untreat d cases (Nardell and Dharmadhikari, 2010). Investigators in 
Lima, Peru screened 250 patients admitted to a female medical ward (Willingham 
et al., 2001). They found that 40 patients who were TB culture positive, including 
65% (26) smear positive and 33% (13) unsuspected TB patients. Of the 40 culture 
positive cases, eight had MDR-TB. Without prompt identification and effective 
treatment of TB and drug resistance in particular transmission from such patients 















1.3.4 Contact Tracing 
Effective contact tracing includes identifying, screening and treating all adult and 
child close contacts of a DR-TB patient. Close contacts are defined as “people living 
in the same household, or spending many hours a day together with the patient in 
the same indoor living space” (WHO, 2006). All contacts should be screened and if 
active TB is suspected a sputum specimen sent for culture and drug susceptibility 
testing. An empirical treatment based on susceptibility results of the index case can 
be started while waiting for DST. Increased morbidity and mortality and 
amplification of resistance can occur from any delays in diagnosis and / or 
treatment (WHO, 2006). Children under five, who don’t have active TB, should be 
given prophylactic treatment for six months.  
In a study by Becerra et al., 693 households where there was an index case with 
M/XDR-TB were investigated. Of the 4503 household contacts, 2.6% (117) had 
active TB at the time the index case started MDR-TB treatment. During the four-
year follow up, 5.3% (242) contacts developed active TB (of the 142 patients who 
had DST results 90.9% had MDR-TB). In light of this high risk of disease among 
contacts, TB programmes should implement systematic household investigations 
for all household contacts of proven M/XDR-TB cases. Any contacts diagnosed as 
having active TB should be assumed to be drug resistant until proved otherwise 
















1.5 M/XDR-TB Management 
1.5.1 Principles for treating M/XDR-TB 
 Design treatment regimens with a consistent approach based on the hierarchy of 
the five groups of anti-tuberculosis drugs (see Table 1.5) 
1. Prompt diagnosis of DR-TB and initiation of appropriate therapy 
2. Use at least four drugs with either certain, or almost certain, 
effectiveness  
3. DST should generally be used to guide therapy, however do not 
depend on DST in individual regimen design for ethambutol, 
pyrazinamide, and group 4 and 5 drugs. (Table 1.5) 
4. Do not use ciprofloxacin as an anti-tuberculosis agent  
5. Design a programme strategy that takes into consideration access to 
high quality DST, rates of DR-TB, HIV prevalence, technical capacity 
and financial resources (Table 1.6)  
6. Treat for 18 months after culture-conversion 
7. Use adjunctive measures appropriately, including surgery, nutritional 
and social support 
8. Aggressively treat XDR-TB whenever possible 
















The rationale for individualised regimens being used for treatment of MDR-TB is 
that the patient receives TB drugs to which they are susceptible. The problem is 
that DST results for second-lines are difficult and not as susceptible as is ideal. 
Results can be easily misread as the margin between the minimum inhibitory 
concentration and the critical concentration is small. The only accurate second-line 
DST tests are for kanamycin, amikacin and the fluoroquinolones. This rationale 
combined with  a lack of second-line drugs available to treat MDR-TB treatment has 
led to standardised treatment regimens for MDR-TB proposed by WHO and 
adopted by South Africa in 2000 (MRC, 2004). Orenstein et al. (Orenstein et al., 
2009) conducted a meta-analysis looking at treatment outcomes in standardised 
versus individualised regimens. Data was analysed from 33 studies from 20 
countries with treatment outcomes for 8506 patients receiving second-line drugs 
for MDR-TB. The overall success rate, either treatment completion or cure was 62% 
(95% CI 58-67%).Among the 29 studies using individualised regimens treatment 
success was 64% (95% CI 59-68%) while in the 5 studies looking at standardised 
regimens had a lower success rate of 54% (95% CI 43-68%). This was not statistically 
significantly however. In 12 studies that combined the two factors with the largest 
effect on success (treatment length of at least 18 months and use of DOTs 
throughout the treatment period), saw the pooled success was 69% (95% CI 64%-
73%), which was significantly higher than the pooled success estimate for the other 
22 studies that did not meet both criteria (585; 95% CI 52-64%). This study 
highlights the importance of closely monitoring patients whom are initiated on 
appropriate treatment regimens and that patients should be treated for at least 18 















 It is also worthy to note that in a meta-analysis carried out by Johnson et al. in 
2009, where 36 studies were reviewed and pooled, successful outcomes occurred 
in 62% (95% CI 57-67) (Johnston et al., 2009), and in that by Akcakir et al. 50% of 
patients had a successful treatment outcome. Factors which increased treatment 
success were found to be treatment duration longer than 20 months, use of more 
than 3 susceptible drugs, individualized regimens, use of fluoroquinolones, and use 
of 2nd line agents in general (Akcakir et al., 2008). Those factors associated with 
worse outcome included male gender 0.61(0.46-0.82), alcohol abuse 0.49(0.39-
0.63), low BMI 0.41(0.23-0.72), smear positivity at diagnosis 0.53(0.31-0.91), 
fluoroquinolone resistance 0.45(0.22-0.91) and the presence of an XDR-TB 
resistance pattern 0.57(0.41-0.80) (Johnston et al., 2009) (26 trials included with a 



















Step 1 Use any available 
 group 1: first line oral agents 
pyrazinamide 
ethambutol 
Begin with any first-line agents that have certain, 
 or almost certain, efficacy. If a first line agent has a high  
likelihood of resistance, do not use it. (E.g. most category 
  IV regimens used in treatment failures of Cat. II do not  
include ethambutol because it is likely to be resistant  
based on treatment history). 
 
Step 2 Plus one of these 
Group 2: Injectable 
Agents 
kanamycin (or amikacin) 
capreomycin 
streptomycin 
Add an injectable agent based on DST and treatment  
history. Avoid streptomycin, even if DST suggests  
susceptibility, because of high rates of resistance  with DR strains 
and higher incidence of ototoxicity. 
Step 3 
 
Plus one of these 




Add a quinolone based on DST and treatment history, In  
cases where resistance to ofloxacin or XDR-TB is  
suspected, use a higher-generation quinolone, but do not 
 rely upon it as one of the four core drugs 
Step 4 Pick one or more of 
Group 4: Second line oral  
bacteriostatic agents 
p-aminosalicylic acid 
cycloserine (or terizidone) 
ethionamide(or protionamide) 
 
Add group 4 drugs until you have at least 4 drugs likely to be 
effective. Base choice on treatment history, adverse  
effect profile and cost. DST is not standardised for the  
drugs in this group. 
Step 5 Consider use of these 
Group 5: Drugs of unclear role  








high dose isoniazid 
clarithromycin 
Consider adding Group 5 drugs in consultation with an  
MDR-TB expert if there are not four drugs that are likely 
 to be effective from Groups 1-4. If drugs are needed  
from this group , it is recommended to add at least two. 
DST is not standardised for the drugs in this group. 
 
a
drug of choice in group 5 
 
b
Thiacetazone is contraindicated in HIV-infected individuals because of the serious risk of 
life-threatening adverse reaction  
Table 1.5     Grouping of drugs, for use in M/XDR-TB treatment, and their use in M/XDR-TB 
regimens 
 
1.5.2  Management challenges 
Clinicians in resource poor settings face several management challenges.  Once the 
diagnosis of MDR-TB has been made, drug-susceptibility testing facilities for 
second-line drugs are often very limited.   In patients who fail WHO regimen 1, it is 
important to establish the degree of drug compliance and the correct diagnosis by 















infected patients opportunistic infections and IRIS need to be considered.  A failing 
regimen 1 should never be replaced by regimen 2 as this represents adding a single 
drug to a failing regimen. Selection of an MDR-TB treatment regimen must be 
based on local drug susceptibility data and previous treatment history. Where 
compliance has been established and there is failure of a MDR-TB treatment 
regimen suspicion of XDR-TB should be raised. This presents an even greater 
challenge because several second-line drugs including moxifloxacin are often not 
available to clinicians in resource-poor settings.  A recent meta-analysis by Jacobson 
(Jacobson, 2010) recently found that moxifloxacin was an independent predictor of 
survival in XDR-TB. Further studies are now urgently required to determine the 
potency of the specific quinolones against extensively-drug resistance stains of M. 
tuberculosis.  High dose isoniazid is a widely available drug worthy of consideration 
in treatment regimens for MDR-TB and XDR-TB (Katiyar, 2008). 
 
 If a diagnosis of XDR-TB is made and there is localised disease and lung function 
permits, then surgery should be considered after the first few months of therapy.  
For the patients who fail to respond to XDR-TB treatment, the absence of dedicated 
hospices, long stay community treatment facilities or isolation facilities makes 
further management of these patients challenging.  The isolation of treatment 
failures with no other therapeutic options and those who are recurrent defaulters 
also present ethical and medico-legal dilemmas(Bateman, 2007). The sheer case 















Africa and many of these patients are now being discharged back into the 
community.                                                                                                                                                                                                                                                           
 
A co-ordinated response in resource poor settings is urgently required to prevent 
further transmission and amplification of the XDR-TB problem.  Recurrent 
defaulting of treatment also presents a dilemma.  Withdrawing treatment is a last 
resort in patients who have recurrently defaulted, where the amplification of drug-
resistance has occurred, and where any further treatment would render the patient 
at high risk for further amplification and transmission of disease.   
 
 1.5.3 Outcomes 
Although the treatment outcomes of MDR-TB are encouraging in some settings 
(Mitnick et al., 2003, Yew and Leung, 2008, Leimane et al., 2010), in resource-poor 
settings like Africa, treatment outcomes are poorer (see table 1.6 for outcome 
definitions). For example, in the West Coast region of the Western Cape, South 
Africa, of 491 MDR-TB patients who received treatment only 49% were cured and / 
or completed treatment (Shean et al., 2008). Although XDR-TB shows encouraging 
treatment outcomes in countries such as Peru (Mitnick et al., 2008) in Africa 
treatment-related outcomes are poorer (Schaaf et al., 2009).  In a hospital outbreak 
of XDR-TB in Kwazulu-Natal, the median time to survival in a population with 
advanced HIV, was approximately two weeks (Gandhi et al., 2009).  Thus, a widely 















prognosis.  XDR-TB is extremely difficult to treat and diverts much needed 
resources away from treatment programmes.   Prevention of XDR-TB is therefore 
paramount.  
 
The first reports on XDR-TB (Migliori et al., 2007b, Migliori et al., 2007a, Kim et al., 
2007, Leimane et al., 2010, Keshavjee et al., 2008) confirmed that patients generally 
have a poorer prognosis as well as fewer treatment options then those with MDR-
TB.  Most of the manuscripts reviewed showed that XDR-TB has a higher probability 
of death, failure, longer hospitalisation, longer treatment duration, as well as a 
longer time to culture-conversion rates. Mortality was almost always increased 
among XDR-TB patients and this may suggest that incurable patients do exist (Table 
1.7) (Migliori et al., 2007b{Sotgiu, 2009 #1489). It will require aggressive case 
finding and treatment regimens for drug susceptible and MDR-TB to prevent a 
























Cure:   A patient who has completed treatment and has 
been consistently culture-negative for five  
consecutive months in the final twelve months 
of treatment.  If one positive culture is reported 
during that time and there is no concomitant 
clinical evidence of deterioration, a patient may 
still be considered cured, provided that this 
positive culture is followed by a minimum of 
three consecutive negative cultures, taken at 
least thirty days apart.    
Treatment completed:  A patient who has completed treatment but 
does not meet the definition for cure due to lack 
of bacteriologic results (i.e. less than five 
cultures were performed in the final twelve 
months of treatment).   
Death: A patient who dies from any cause whilst on DR-
TB treatment 
Treatment default:   A patient who interrupts DR-TB treatment for 
two or more consecutive months for any reason.   
Treatment failure:   A patient who has had two or more of the five 
consecutive cultures taken in the final twelve 
months are positive, or if any one of the final 
three cultures are positive.     
Transfer out:   A patient who has been transferred to a 
reporting unit in another province and for whom 
the treatment outcome is unknown.    
Treatment stopped due to adverse drug 
reactions 
A patient who develops adverse drug reactions 
whilst on DR-TB and could not continue 
treatment in spite of the management of the 
adverse drug reactions as per protocols and the 
decision has been taken to stop treatment. 
Treatment stopped due to other reasons:  A patient who could not continue on DR-TB 
treatment for any other medical reason than 
adverse drug reactions, and a decision to stop 
treatment was made.   
Still on treatment:  A patient who for any reason is still on treatment 
at the time of submission of treatment outcome 
report. 
The outcome definitions are based on bacteriological culture as a monitoring tool: 
 




















MDR vs. XDR 
n (%) 
Failure 
MDR vs. XDR 
n (%) 
Death 
MDR vs XDR 
n (%) 
(Ghandi et al., 
2006b), Lancet 
NA NA NA NA 
vs. 52 (98%) 
(Migliori et al., 
2007b), EID 
SS: 41 vs 110days 





Vs 4 (36.4%) 
P:<0.001; RR: 5.45 
(Migliori et al., 
2007a), ERJ 
 
SS: 56 vs 110 days 




vs 12 (18.7%) 
32 (8.9%) 
Vs 12 (18.7%) 
P; 0.016; RR: 2.12 
43 (11.9%) 
Vs 14 (21.9%) 
P: 0.03; RR: 1.84 
(Kim et al., 2007), 
CID 
NA 109 (64.9%) 
vs 23 (53.5%) 
29 (17.3% 
vs 11 (25.6%) 
p 0.21; RR: 1.48 
13 (7.7%) 
Vs 6 (14.0%) 
P: 0.20; RR: 1.8 
(Mitnick et al., 
2008), NEJM 






Vs 5 (10.4%) 
P:0.7; RR: 0.83 
123 (20.4% 
Vs 11 (22.9%) 
P: 0.67; RR: 1.12 
(Chan et al., 
2008), NEJM 
 
NA Odds ratio 
(MDR) 23.4 




(Keshavjee et al., 
2008), Lancet 
C: 2 vs 2 months 
(median) 
386 (66.7%) 
Vs 14 (48.3%) 
49 (8%) 
Vs 9 (31%) 
P: 0.65;RR: 1.38 
29 (5%) 
S 2 (7%) 
P: 0.65; RR: 1.38 
(Eker et al., 
2008), EID 
 
SS: 53.5 vs 88 
days 
C 61.5 vs 117 days 
(median) 
105 (59.3%) 




Vs 1 (14.3%) 
P: 0.5; RR 1.81 
(Kwon et al., 
2008), CID 
NA 84 (66%) 
Vs 18 (67%) 
NA NA 
(Lai et al., 2008) 
CID 
NA NA NA NA 
(Banerjee et al., 
2008), CID 




Vs 7 (41.2%) 
NA 80 (15.3%) 
Vs 5(29.4%) 
P:0.4; RR: 1.41 
(Bonilla, 2008), 
PlosOne 




Vs 18 (4(%) 
ITR* 
50 (10%) 
Vs 5 (14%) 
P: 0.005; RR: 1.34 
ITR* 
39 (8%) 
Vs 8 (22%) 
P: 0.005; RR: 2.74 
(Kim et al., 2008), 
AJRCCM 
NA 615 (46.2%) 
Vs 22 (29.3%) 
53 (4%) vs 12 
(16%) 
124 (9.3%) vs 20 
(26.7%) 
Median SS: 53 vs 110 days 
C: 61 vs 117 days 
- - - 
*Individualised treatment, MDR: multidrug-resistant; XDR: extensively drug-resistant 















 1.5.4 Role of surgery 
The role of surgery in M/XDR-TB is controversial. After effective drugs were 
discovered to treat MDR-TB, surgery was used less and less until it virtually 
disappeared in the 1970s from case management strategies. The question now 
being asked is what to do in M/XDR-TB patients who are resistant to virtually all the 
available drugs. These patients to all intents and purposes are back in the pre- 
chemotherapy days.  
 
Almost all of the guidelines and recommendations mention the role of surgery, 
although in a very secondary role (American Thoracic Society et al., 2003). Surgery 
is however recommended in those patients who meet the following three criteria: 
(1) localised disease with good chances of complete or nearly complete resection 
and adequate expected post operative lung function; (2) adequate pulmonary 
function and (3) enough available drugs to formulate an acceptable drug regimen to 
ensure post-surgery stump healing (Caminero, 2006). 
 
Surgical interventions together with individualised chemotherapy regimens have 
shown good results of >90% in a number of studies but there is little data on 
surgical interventions on XDR-TB patients. A  study of adjunctive surgical 
intervention in XDR-TB patients, conducted by Dravniece et al., showed that despite 
failure of pharmacological treatment in 15 out of 17 patients, eight (47%) of these 















 1.5.5 Adverse drug reactions 
Virtually all patients will report adverse effects to second-line drugs and it is known 
that second-line drugs are more toxic then first-line drugs. Close monitoring of 
patients is essential. Table 1.8 below lists all the important side effects and the 


























Audiology (hearing test) Monthly if possible 
Levels monthly 
 
Serum creatinine and potassium, monthly high-
risk patients more often 
















Clinical observation. Prevent by initially    
splitting dose or increasing dose or   increasing 
dose gradually 
 
Jaundice. Serum alanine transferase and    
bilirubin 
 
Thyroid-stimulating hormone levels (freeT4). 
At least 6 monthly 
Cycloserine  
(or terizadone) 
Psychosis, seizures, parasthesia 
depression 






Clinical observation  





Pancreatitis (abdominal pain) 
Optic neuritis 
Full blood count. Weekly at first, then monthly 
Serum lactate level 
Clinical observation 
Clinical and serum amylase as indicated 
Vision testing 
 
*Adverse drug effects of first-line drugs and antiretroviral drugs in patients infected with HIV often 
have overlapping adverse drug effects  
Table 1.8  Important adverse drug effects of second-line drugs, and tests to  

















Adverse effects should be treated early and failure to do so could lead to poor 
adherence or irreversible problems such as hearing loss or peripheral neuropathy 
and ultimately death in extreme cases (e.g. acute renal failure in capreomycin). 
Adverse drug reactions of first-line drugs and antiretroviral drugs in patients 
infected with HIV often have overlapping adverse effects with second-line drugs, 
such as gastrointestinal disturbance (almost all), hepatitis (INH, d4T, ddl.), central 
nervous system effects (INH, efavirenz), pancreatitis (d4T, ddl) and lactic acidosis 
(d4T, ddl, AZT, 3TC)(WHO, 2008). 
 
1.6    Study objectives and rationale 
1.6.1 Background/ motivation: 
The rise in DR-TB is a global public health concern, particularly in resource-
limited countries with a high burden of TB.  Multidrug-resistant TB (MDR-
TB), with resistance to the two first-line TB drugs isoniazid (INH) and 
rifampicin (RIF), has been recognized as a major problem in TB management 
and control.  
 Recently, a joint global survey by the WHO and the US CDC identified XDR-
TB in  all regions of the world, thereby recognising this as a new threat to 
TB  control (Centers for Disease control and Prevention (CDC) 2006). This 
 concern was further heightened with the identification of an XDR-TB 
 outbreak involving fifty-three cases in South Africa (Gandhi et al., 
2006a)(Gandhi et al. 2006).  This  outbreak showed exceptionally high mortality 















in the absence of DST the evolution of MDR-TB and XDR-TB was inevitable 
(Pillay & Sturm 2007).  Scarce drug resistant data from Africa on prevalence of 
resistant TB patterns, while lower then Asia and Europe is increasing and 
together with HIV can fast track XDR-TB into an  uncontrollable epidemic.     
 
 
XDR-TB threatens to destabilize TB control in South Africa. However, there are few 
data that inform and guide the rational implementation and planning of control 
strategies, and treatment services, for XDR-TB in this country. Current tools to 
diagnose tuberculosis have poor susceptibility and  results are not available for 
several weeks, whilst tools used for the diagnosis of drug-resistant TB are 
cumbersome and not widely available. Treatment options, because of the high level 
resistance, are severely limited in patients with XDR-TB. Adverse drug reactions 
(ADRs) may be an important  reason for treatment interruption in XDR-TB and 
influences patient perceptions about toxicity and hence compliance. There are 
hardly any data about the risk factors for ADRs in patients with XDR-TB, whether 
ADRs  impact on treatment-related outcomes, and how drug regimens should be 
monitored. The main aim of this study was to evaluate treatment-related 
















1.6.2 Aims and objectives 
1. To evaluate treatment-related outcomes (early outcomes and ADRs)  and 
DST patterns in XDR-TB      patients in South Africa. 
Sub aim 1: What are the early outcomes (conversion and death) in 
XDR-TB patients? 
Sub aim 2: What proportion of XDR-TB is due to primary and 
acquired resistance? 
Sub aim 3: What is the relationship between patient-related factors 
(demographic, clinical and laboratory) and treatment outcome 
(sputum conversion and death) in XDR-TB. 
surgery? 
 Sub aim 4: What is the morbidity and mortality, as well as treatment 
 outcome in HIV-infected XDR-TB patients compared to uninfected 
 patients (and in those HIV-infected persons who access and receive 
 treatment with HAART vs. no HAART)? In the latter group when 
 should HAART be initiated in relation to the initiation of the XDR-TB 
 treatment and what are the side effects of the ARVs in relation to 
 second-line drugs? 
















2. To evaluate extent, severity and toxicity of drugs used for XDR-TB 
  Sub aim 1: How well tolerated are XDR-TB regimens? 
Sub aim 2: Do HIV-infected people have more severe adverse drug 
reactions than those whom are HIV-uninfected? 
Sub aim 3: How are treatment outcomes affected by severe adverse 






























Chapter 2 Methodology  
 
In this chapter I will detail the design of my study, how the study was constructed and 
executed, and a description of the study sites and participants. 
2.1     Study setting and participants 
2.1.1  Gordonia Hospital 
2.1.2 Sizwe Hospital 
2.1.3 Jose Pearson Hospital 
2.1.4 Brooklyn Chest Hospital 
2.2      Diagnosis of XDR-TB 
2.3      Treatment regimens 
2.4      Outcomes  
2.5      Strain typing 
2.6      Data handling and statistical analysis 
Figures 
Figure 2.1     Outlines the centre-specific dates from which study enrolment started 
and ended (1 February 2008 was the enrolment censor date and 1 September 2008 
was the follow-up censor date so that there could be at least a six-month follow up 
on all patients included in the analysis). 
















2.1  Study setting and participants 
The case records of 227 patients diagnosed with XDR-TB between August 2002 (the 
start of the DOTs plus programme in South Africa i.e. a standardised treatment 
regimen for MDR-TB patients) and the end of February 2008 were retrospectively 
reviewed. Patients had to be 18 years or older to be included in the study. This was 
a retrospective observational cohort study. 
The 227 patients included in this study had either: (i) been admitted as an inpatient 
in one of the 4 dedicated XDR-TB inpatient facilities in South Africa, or (ii) had died 
during the interval between sputum acquisition date and sputum results confirming 
the diagnosis of XDR-TB or (iii) the patient died while awaiting admission to the 
specialised hospital for treatment initiation, or (iv) the patient died shortly after 
being admitted before treatment commencement.  The patients were admitted to 
the following hospitals: 
2.1.1 Gordonia Hospital, in the town of Upington in the Northern Cape 
Province is a level one, 189-bedded hospital, consisting of 5 wards, one 
of which is used for housing patients with MDR and XDR-TB. This region 
has amongst the highest documented incidence of tuberculosis (TB) in 
the world at 800 cases per 100 000 people. (Beth Engelbrecht).  
Sixteen of the study patients were registered at Gordonia and the HIV 
rate was 12.5% (2/16). 
 
2.1.2 Sizwe Hospital, just outside Johannesburg, in the Gauteng Province, has 















highly infectious haemorrhagic viral diseases. It is also Gauteng’s referral 
hospital for inpatient care of MDR and XDR-TB patients. (AVERT). 35 
study patients were registered at Sizwe and the HIV rate was 66% 
(23/35). 
 
2.1.3 Jose Pearson in Port Elizabeth, Eastern Cape is a South- African National 
Tuberculosis Association (SANTA) centre dedicated to the inpatient 
treatment of MDR and XDR-TB. Currently it has 250 beds for the 
inpatient treatment of MDR-TB patients as well as 134 beds for XDR-TB.  
Fifty-nine study patients were from Jose and the HIV rate was 57.6% 
(34/59). 
 
2.1.4 Brooklyn Chest Hospital (BCH) in Cape Town is the  referral centre for 
XDR-TB patients in the Western Cape province who are admitted until 
sputum culture-conversion or until they are deemed (by the provincial 
review board) to be a treatment failure. Drug susceptible and MDR-TB 
patients are also admitted to BCH. Eighty-nine study patients were 











































*Approval for this section of the cohort was obtained for this 
time period only
 
Figure 2.1    Outlines the centre-specific dates from which study enrolment started and 
ended. The first of February 2008 was the enrolment censor date and 1 September 2008 
was the follow-up censor date so that there could be at least a six-month follow up on all 
patients included in the analysis. 
 
Documents which were carefully reviewed included hospital folders, the notes 
written by the doctors and nurses, clinic folders where available, a data base in use 
at BCH (TB data) and the patient’s paper-based MDR-TB forms which have been in 
use since the early 1990’s. Data was entered into case record forms (CRF’s - 















treatment taken and outcomes for each TB episode. Concomitant illnesses, HIV 
status and history, history of any surgery - thoracic and /or other, adverse drug 
reactions and all the patients laboratory results, were also recorded. 
 
The standardised CRF was completed by myself in the Western and Northern Cape. 
At Sizwe the data was captured by a clinician working at the hospital and the CRF’s 
were then couriered down to the Lung Infection and Immunity Unit (LIIU) in Cape 
Town. The data from Jose Pearson was captured, on a separate database, by a 
trained health care worker working for the South- African Medical Research Centre 
(SAMRC). This data was then merged with the other data.  All data was entered 
onto an Excel spreadsheet by a trained data capture person. 
 
 A summary of the study plan and details of the treatment facilities is outlined in 
Figure 2.2 All patients diagnosed with XDR-TB were admitted to the relevant facility 
until sputum smear conversion or until they were deemed a treatment failure as 
decided by the relevant provincial review boards. 
 
Twenty-eight of the 227 enrolled patients were excluded from the study:  Two 
participants were excluded as they were children under the age of 18. In eight 
patients the sputum culture result was unknown at XDR-TB treatment initiation and 
the one-month sputum culture was negative so it was not clear if these patients 















transferred from the Eastern Cape to the Western Cape had been entered into the 
database twice. In four patients there was insufficient data for them to be included 
and in 13 patients the HIV status was unknown or the patient had refused testing. 
This left 199 enrolled patients for further analysis (Figure 2.2).  
2 – Children under 18
8 – Unknown sputum culture 
status at  XDR- TB treatment 
initiation 
1 – Patient transferred From EC
to WC
4 – Insufficient data
13 – HIV (refused/ unknown) 
HIV +
n = 82











































Ethical approvals were obtained for each site.  The Lung Infection and Immunity 
Unit (LIIU) obtained ethical approval from the University of Cape Town, Sizwe from 
the University of the Witwatersrand University, and the South- African Medical 
Research Council from their own ethics board. Provincial approvals were also 
obtained from the different Provincial Research boards. 
2.2  Diagnosis of XDR-TB 
All new TB cases entering the health system were diagnosed and treated based on 
smear microscopy results. The National TB policy recommended that culture and 
DST for isoniazid, rifampicin and ethambutol be performed in all new TB cases who 
had not converted by month three, in all retreatment cases at presentation and in 
high risk patients.   High risk patients include prisoners, health care workers and 
contacts of MDR and XDR-TB patients. As part of the DOTs-plus strategy, MDR-TB 
patients who were still culture positive after nine months of treatment had sputum 
sent for second-line testing as part of the DOTs plus strategy.   XDR-TB patients 
were retrospective diagnosed, prior to the XDR-TB definition, based on the nine-
month culture and DST results. 
Susceptibility to INH and rifampicin was done by the HAIN probe assay if the smear 
microscopy was positive.  If the smear microscopy was negative, the isolate was 
cultured by conventional methods and then DST done by polymerase chain reaction 
(PCR). Second-line testing was performed using the indirect method on solid media 
(7H11) at a dedicated Provincial TB laboratory (Cape Town, Port Elizabeth, 
Kimberley and Johannesburg) using standardised reagents and methodologies. This 















 Sputum isolates which showed resistance to isoniazid and rifampicin were 
automatically sent for second-line testing to ethionamide, ofloxacin, amikacin or 
kanamycin) Testing to the first line injectable, streptomycin (an amino glycoside) 
and pyrazinamide (PZA) was also done in selected centres. In Kimberley (Northern 
Cape) DST was done for kanamycin, whereas in the other provinces testing was 
done for amikacin under the premise that the cross resistance between kanamycin 
and amikacin is high (Kruuner et al., 2003, Tsukamura, 1975, Tsukamura, 1980). 
 
In this study patients whose isolates were resistant at diagnosis (time of initial 
sputum collection) to at least isoniazid, rifampicin, a fluoroquinolone and at least 
one of the second-line injectable agents (i.e. amikacin, kanamycin or capreomycin) 
were deemed to have XDR-TB. In early 2007, with the newly adopted definition of 
XDR-TB and revised guidelines second-line DST became more widely available. 
Thus, XDR-TB was only widely diagnosed and treated from late 2006 or early 2007 
with a limited number of cases identified retrospectively from the pre-2006 period. 
DST to capreomycin, terizidone and the newer generation fluoroquinolones was not 
available within the national health laboratories services. However, to gain further 
insight into resistance patterns  DST was performed on capreomycin in 56 isolates 
obtained from patients in the Western Cape in accordance with the US CDC 
guidelines (Isenberg, 2004.).  This testing was done genotypically at the Molecular 
and Cellular Biology Department at the Health Science Faculty, University of 
Stellenbosch.   















Prior to the diagnosis of XDR-TB any previous episodes of MDR-TB  were generally 
treated with a standardised regimen comprising of kanamycin, ofloxacin, 
ethionamide, ethambutol and pyrazinamide (terizidone was substituted for 
ethambutol in patients demonstrating resistance to ethambutol). Hospitalisation 
for initiation of MDR-TB treatment and monitoring until culture-conversion was 
recommended but lack of bed capacity often precluded this. 
 
For initiation of treatment for XDR-TB treatment hospital admission was mandatory 
as specified in the MDR-TB national guidelines.  Treatment was individualised with 
the use of capreomycin and para-aminosalycilic acid (PAS) as the anchor drugs. 
These two drugs were released in South Africa specifically for the treatment of XDR-
TB. Other first and second-line drugs were used at the discretion of the attending 
clinician or those to which the organism demonstrated susceptibility while taking 
into account the patient’s previous treatment history.  
 
Linezolid is currently unavailable through the National TB Programme. Clofazamine 
was used in Sizwe for inclusion in an XDR-TB regimen and moxifloxacin at Jose 
Pearson. Patients from Khayelitsha, in the Cape Metropole, received moxifloxacin 
as part of a community treatment project.  The drug was sponsored by Médecins 
Sans Frontières (MSF). Highly active antiretroviral therapy (HAART) was offered to 
all HIV-infected patients at the discretion of the attending clinician.  















The date on which the sputum sample was taken and from which XDR-TB was 
cultured was deemed the date of diagnosis of XDR-TB. There was a measurable 
delay between diagnosis and XDR-TB treatment initiation due to the length of time 
it takes to perform culture and DST. Conversion was defined as to have occurred 
when two consecutively negative cultures were obtained, one month apart, and 
where there was proven culture positivity at treatment initiation.  Conversion is 
then measured in days from treatment initiation date until the take date of the first 
negative culture.  
 
 Widespread and targeted screening for XDR-TB was only available in many centres 
from late 2006 to early 2007. Therefore the majority of the cohort had a relatively 
short follow-up period and we thus focussed on early outcomes [conversion 
(Chapter 4) mortality (Chapter 5) and ADR’s (Chapter 6)].   
 
2.5  Strain typing 
To see whether there was any additional resistance acquisition during XDR-TB 
treatment, a subset of 52 XDR-TB isolates, were obtained from the NHLS, where 
they had been stored, from patients from the Western Cape and were genotyped 
by IS6110 DNA fingerprinting (Warren, 2006) spoligotyping (Kamerbeek, 1997) and 
DNA sequencing of the inhA promoter and the katG, rpoB, embB, pncA, gyrA and rrs 
genes. Transmission chains were defined by isolates having identical IS6110 DNA 
















2.6  Data handling and Statistical analysis 
A data risk management tool, including double data entry, was used to ensure data 
integrity. Categorical variables were compared using the chi-square test or Fisher 
exact test for smaller samples (i.e. all expected frequencies not ≥ 5) and continuous 
variables because data does not follow normal distribution, the non-parametric 
Mann-Whitney or Kruskal-Wallis tests were used.  
Kaplan-Meier’s method (event over time analysis) was used to calculate 
probabilities of events at different time points and the Log-rank test was used to 
compare these probabilities by group. Our approach to survival data were the Cox 
proportional hazards regression models which were fitted to determine risk factors 
associated with outcomes in a time-to-event based analyses. Variables found to be 
significantly associated with the outcome (p<0.05) were included in the final model. 
The proportionality assumption of the Cox models was tested using –ln [–ln 
(survival)] curves and regression of scaled Schoenfeld residuals on functions of time. 
The assumption of uninformative censoring was examined by plotting observed 
survival times against the values of the explanatory variables included in the model. 
In addition, sensitivity analyses were conducted to account for patients excluded 















Chapter 3:  Diagnosis, susceptibility patterns and transmission 
dynamics in patients with XDR-TB 
4.3     Introduction 
3.2      Methodology 
3.2.1 Study setting and participants 
3.2.2 Diagnosis of XDR tuberculosis 
3.2.3 Treatment regimens 
3.2.4  Contact Tracing 
3.3 Results 
3.3.1  Demographics 
3.3.2 Diagnosis  
3.3.3 Strain typing 
3.3.4 Treatment regimens 
3.3.5 Contacts of XDR-TB patients 
3.3.6 Prisoners 




Table 3.1:  Demographic and clinical characteristics of the cohort (n=199) stratified by HIV 
status  
















South Africa has a population of nearly 48 million people, an HIV prevalence of 11% 
in 2008, a tuberculosis notification rate of 948 per 100 000 population in 2007, and 
a notification of more than 7000 MDR cases in 2007 (WHO, 2010). National policy 
recommends that drug-susceptibility testing should be done for rifampicin, 
isoniazid, and ethambutol in all new cases of tuberculosis who have not culture-
converted by two to three months, all retreatment cases at presentation, and high-
risk patients (e.g. prisoners, contacts of MDR-TB patients, HCW’s etc.) at 
presentation (Health, 2010). 
 
Rapid diagnosis of XDR-TB has several important benefits. Firstly, optimal treatment 
can be quickly initialised (before routine culture and DST results become available), 
thus reducing the length of time that inappropriate and sub-optimal therapies are 
administered. This is crucial to reduce the period of time on inappropriate therapy, 
which can lead to the selection of further drug resistance and possible development 
of totally drug-resistant tuberculosis. Secondly, earlier diagnosis and isolation of 
patients will reduce the likelihood of transmission of drug resistant TB to contacts. 
Several rapid techniques for drug susceptibility testing have become available, 
(Dheda et al., 2010a, Schaaf et al., 2009, Morgan et al., 2005, Pai et al., 2005) which 
make it possible to consider intensifying detection of patients with XDR-TB, and 
which would enable results to be reported to clinicians in “real time” impacting 

















Molecular strain typing techniques like RFLP have revolutionised epidemiological 
investigation of TB cases. It is useful for large-scale epidemiological studies to see if 
strains are part of a true cluster or a local outbreak and to investigate laboratory 
cross contamination. There are few data about whether XDR-TB in the Western 
Cape is due to primary or acquired resistance.  
 
XDR-TB was only widely diagnosed and treated from late 2006 / early 2007, with a 
limited number of cases identified retrospectively from the pre-2006 period. As no 
international consensus on management of XDR-TB patients existed at that time, 
the WHO advocated the use of the same general principles as those for treatment 
of MDR-TB.  While we know that MDR-TB treatment outcomes are poor there is 
little data on treatment outcomes in XDR-TB (Chapters 4 and 5), what drugs are 
being used in regimens and the adverse side effect profiles of these drugs (Chapter 
6). 
 
A grossly neglected area in the management of XDR-TB is the screening of close 
contacts.  In many high burdened under-resourced countries there is no capacity to 
perform active case finding. This is a missed opportunity to identify and treat 
patients and thereby assisting in bringing down morbidity and mortality rates 
















Overcrowding, lack of isolation facilities and basic infection control within prisons 
exacerbates transmission of tuberculosis, and remains a global problem.  Russia has 
been an example of this in recent years where the prison system has been 
identified as helping in fuelling the TB epidemic. In 1997 notification rates among 
the 1.1 million incarcerated people was 4 000/100 000 several times higher than 
among the general population where the rate was 81.3/100 000 (Academies, 2009). 
At the beginning of 2007 it was estimated that there were about 166 000 people 
incarcerated in 237 operational South- African prisons where actual capacity was 
115 000, some 40% over capacity. It is also estimated that 20.5% of these prisoners 
are HIV-infected (2009). However, there is little data from South- African prisons 
about TB prevalence and the presence of XDR-TB.  
  
Finally, although surgical intervention for patients who have run out of 
chemotherapeutic options, or are likely to relapse, or who remain consistently 
sputum culture positive, is considered a suitable adjunct, (Van Leuven et al., 1997, 
Mohsen et al., 2007) there are few data about surgical outcomes in XDR-TB.  
Moreover, most surgical studies were performed in MDR-TB patient cohorts and 
further studies need to be performed in patients with XDR-TB (Van Leuven et al., 

















3.2.1 Study setting and participants 
We retrospectively reviewed the case records of 227 patients, over the age of 18 
years, diagnosed with culture proven XDR-TB. In the final analysis we analysed data 
from 174 patients who started XDR-TB treatment within a hospital setting. These 
patients were diagnosed between August 2002, at the start of DOTs-plus and 
February 2008. They were diagnosed at four of nine dedicated provincial facilities 
for the treatment of XDR tuberculosis in South Africa.  
 
 3.2.2 Diagnosis of XDR tuberculosis 
According to national policy, isolates resistant to isoniazid and rifampicin would 
undergo second-line testing (kanamycin or amikacin and ofloxacin), only if 
requested. Previously in line with DOTs-plus guidelines DST to second-line drugs 
was done at nine months although there were clinicians who still performed DST to 
second-line drugs if the patient’s culture was still positive at the end of the 
intensive phase (i.e. at the end of the four months of an injectable agent). In early 
2007, with the newly adopted definition of XDR tuberculosis and revised guidelines, 
second-line drug-susceptibility testing became widely available with the policy 
changing so that all isolates demonstrating resistance to isoniazid and rifampicin 
















Second-line testing was done by use of the indirect method on solid media 
(Middlebrook 7H11, Becton Dickinson, Le Pont de Claix, France) at dedicated 
provincial tuberculosis laboratories in Cape Town and Port Elizabeth. Liquid media 
(The BACTEC MGIT 960 System, Becton Dickinson) was used in Johannesburg. Both 
of these methods were used with standardised reagents and methods, which did 
not change during the study.  
 
DST to capreomycin, terizidone and fluoroquinolones other then ofloxacin was not 
available within the Provincial laboratories. However, to gain further insight into 
prevailing patterns we performed DST to capreomycin in 56 isolates obtained from 
patients in the Western Cape in accordance with Centers US CDC guidelines 
(Isenberg, 2004.).   
 
3.2.3 Treatment regimens 
The XDR-TB drug regimens included three to four drugs with known efficacy and to 
which the patient had not been previously exposed. All XDR-TB regimens included 
an injectable and other medication added based on the susceptibility profile and 
the patient’s previous TB drug history. Group 5 drugs (Table 18, pg 55) were not 
recommended for routine use in treatment of M/XDR-TB as the efficacy against 
Mycobacterium tuberculosis had not been proved. These drugs were used, 















regimen needed to be strengthened. Drugs with known unmanageable side effect 
profiles or to which the patient was allergic were omitted from the regimens. 
 
Capreomycin and para-aminosalicylic acid (PAS) were introduced into the National 
TB Programme in early 2007 specifically for the use in XDR-TB regimens. Linezolid is 
currently unavailable through the National TB Programme and clofazamine (despite 
being the drug of choice in group 5 (Table 1.8 page…55) and moxifloxacin was being 
used only in selected centres on a limited basis.  Moxifloxacin was only accessible at 
Jose Pearson in the Eastern Cape, and through a nong vernmental organisation 
(MSF) on a restricted basis in the Western Cape (Khayelitsha). HAART was offered 
to all HIV-infected patients at the discretion of the attending physician. The national 
TB policy was recently amended and terizidone now replaces ethambutol in the 
standardised MDR-TB regimen.  
 
3.2.4  Contact Tracing 
Effective contact tracing includes identifying, screening and treating, all adult and 
child, close contacts of a drug-resistant TB patient already diagnosed. Close 
contacts were defined as “people living in the same household, or spending many 
hours a day together with the index patient in the same indoor living space” (WHO, 
2006).  All contacts should be screened and if active TB is suspected sputum sent off 
for culture and susceptibility. Increased morbidity and mortality and amplification 















in South Africa with regards to contact screening of XDR-TB patients was that once 
a patient was diagnosed as having XDR-TB, the house was visited, an assessment 
done, and all household contacts screened (WHO, 2006).  
 
3.3 Results 
  3.3.1 Baseline demographic, clinical and laboratory characteristics 
In the final analysis we analysed data from 174 patients who started XDR-TB 
treatment within a hospital setting. The patients were generally young with a 
median age of 33 years, (IQR 26-45). Whilst there was only one white patient 
identified, 39.6% (69/174) of the XDR-TB patients were of mixed ethnicity and 
59.8% (104/174) of black ethnicity. Gender was roughly equal with 51% of patients 
being female (89/174) and 49% males (85/174). Interestingly, in this study, HIV 
infected and uninfected rates were similar [47% (82/174) vs. 53% (92/174)]. 
Demographic variables of the whole cohort of 199 patients stratified by HIV status 






















Negative Positive P-value 
Total number (%) 105(52.8) 94 (47.2)  
 
Gender   0.002 
    Female 42 (40.0) 58(51.7)  
    Male 63 (60.0) 36(38.3)  
 
Age, median (IQR)  32.1(25.9– 44.6) 36.1(28.0–45.8) 0.11 
 
Ethnicity   <0.0001 
    Black 34(32.4) 80(85.1)  
    Mixed origin 70(66.6) 14(14.9)  
    White 1(1) 0(0)  
 
Employment   0.68 
    Employed 15(14.3) 10(10.6)  
    Unemployed 80(76.2) 73(77.7)  
    Unknown 10(9.5) 11(11.7)  
 
Smoking history   0.09 
    Yes 37(35.2) 20(21.3)  
    No 27(25.7) 31(33.0)  
    Unknown 41(30.0) 43(45.7)  
 
Smear status   0.60 
     Positive 16(15.2) 17(18.1)  
     Negative 89(84.8) 77(81.9)  
 
XDR-TB treatment status   0.94 
     Treated      92(87.6) 82 (87.2)  
     Not treated      13(12.4) 12(12.8  
 
History of prison contact    0.20 
    Current 5(4.8) 3 (3.2)  
    Previous 12 (11.4) 5 (5.3)  
    None 32 (30.5) 40 (42.6)  
    Unknown 56 (53.3) 46 (48.9)  
 
Days from sputum acquisition to result, 
median (IQR)  53(20.0 – 77) 39(16.5 – 82.5) 0.40 
 
Days from result to treatment initiation, 
median (IQR)  20(8.0 – 39.8) 19(5.5 – 23.5) 0.20 
 
Weight (kg) at start of treatment, median 
(IQR)(n=72)  48(39.9-53.3) 49.7(42-60) 0.46 
 
Number of prior sensitive episodes, 
median(range)  1(1 – 5) 1(1 – 4) 0.35 




















 test used for all categorical variables, and Mann-Whitney test for all continuous    
variables.  
  ± 
significant inter-group difference because the HIV-infected group had minimal dispersion about 
the median compared to HIV-uninfected group, which had a positively skewed spread.  
 
Table 3.1: Demographic and clinical characteristics of the cohort (n=199) stratified by HIV 
status 
 
3.3.2 Diagnosis  
Fourteen percent or 25 of the 199 documented XDR-TB patients did not start 
treatment. Twenty-one of these patients either died prior to confirmation of the 
diagnosis (DST result) or prior to being traced and admitted to a suitable facility to 
initiate therapy.  The remaining four patients were admitted to the specialised XDR-
TB unit but treatment was not initiated due to the unsatisfactory condition of the 
patient on admission. Sputum “take” date to DST result acquisition ranged from 
16.5 to 82.5 days, with a median time of 53 days in HIV-uninfected and 39 days in 
HIV-infected patients. Days from sputum DST result acquisition to treatment 
initiation ranged from 8 - 39 days. The median length of time from sputum 
collection (primary sputum used to make the XDR-TB diagnosis) to treatment 



















3.3.3 Strain typing 
 
Seventy four percent of XDR-TB patients had previous culture-confirmed MDR-TB 
(Table 3.1), suggesting acquisition of additional resistance during this treatment 
period. To test this notion genotypic data from 52 patient isolates in the Western 
Cape were analysed. Seventeen XDR-TB patients had an M. tuberculosis isolate with 
a unique IS6110 genotype, while the remaining 35 XDR-TB cases had an M. 
tuberculosis isolate, which could be grouped into one of six clusters. Of these 
clustered cases only 19% (10) showed identical resistance causing mutations to 
both first and second-line drugs, suggesting that resistance to second-line drugs 
was acquired in 81% of the patients from the Western Cape.  
 
3.3.4 Treatment regimens 
One hundred and seventy-four patients initiated treatment with a regimen 
containing a backbone of capreomycin and para-aminosalicylic acid (PAS), and 
received a median of 7 (IQR 6-8) drugs. The most common drugs used in the 
regimens in this cohort were (the denominator in this analysis is 115 as Jose 
Pearson, in the Eastern Cape was omitted, due to several fields not being captured): 
terizadone 91.3% (105/115), followed by capreomycin 90.4% (104/115), PAS at 87% 
(101/115), clarithromycin and PZA both 69% (80/115). Capreomycin was given until 
the attainment of at least 3 negative cultures, after which it was stopped and 
patient was discharged. The other drugs were continued for the remainder of the 
treatment period or were stopped at the discretion of the treating medical officer 















XDR-TB treatment, 63% (52/82) received highly active antiretroviral therapy (the 
commonest regime used in 50% of the patients was zidovudine, lamivudine, and 
efavirenz).  






(number of patients 
resistant to 
treatment/number of 
susceptibility tests done in 
treated patients 
Ethambutol  103 (59) 6.8(4.0-11.4) 62/117(53%) 
Pyrazinamide  140 (80) 7.2(3.3-11.5) ND 
Amikacin 3(2) 4.2(2.1-5.8) 124/124(100%) 
Capreomycin 162(93) 7.2(3.1-12.1) 22/42(52%0 
Kanamycin 4(2) 13.4(4.8-15.6) 50/50 (100%) 
Moxifloxacin 14(8) 12.1(10.4-18.3) ND 
Ofloxacin 31(18) 8.1(4.2-12.0) 174/174(100%) 
Terizidone 147(84) 9.2(3.5-12.1) ND 
Ethionamide 107(61) 8.0(3.2-11.9) 59/167(35%) 
Para-aminosalicylic acid 156(90) 7.3(3.7-12.2) ND 
Amoxicillin-clavulanate 66(38) 7.1(3.1-12.2) ND 
Clarithromycin 77(44) 8.6(3.7-13.9) ND 
Clofazamine 28(16) 8.7(4.3-14.3) ND 
Dapsone 95(55) 6.6(3.1-11.6) ND 
Azithromycin 11(6) 7.9(2.8-12.1) ND 
Isoniazid /thiacetazone 2(1) 7.8(1.9-13.7) ND 
Rifabutin 1(<1) NA ND 
Streptomycin 1(<1) NA ND 
Data are number (%), unless otherwise indicated. ND = not done. NA = not applicable 
















The median duration of follow-up from treatment initiation to event (death, loss to 
follow-up or the censor date) was 6.9 months (IQR 3.1 to 12.0) and duration of 
treatment with injectable drugs was 13.4 months (IQR 4.7 - 15.5). At the time of 
data analysis, three out of the 13 culture converters had completed treatment, two 
of whom were HIV infected. Two patients remained culture-negative and on 
treatment and one patient died after culture-conversion – (these cases were all 
from the Western Cape for whom there was follow-up data after the study).  
 
3.3.5   Drug susceptibility testing: 
Overall drug susceptibility profiles did not differ with HIV status or when HIV-
infected patients were stratified by CD4-cell count. Resistance, to ethambutol was 
high at 55.8%, and resistance to ethionamide 42.8% (Table 3.2). 58% (33/57) of 
available isolates that were retrospectively tested for susceptibility to capreomycin 
were resistant, and 74% (42/57) of patients were given the drug after the isolate 
was harvested for susceptibility testing. Only 48% (20/57) of these patients had 





















Fifty percent (33/66) had documented contacts who had a history of previous active 
TB. A more detailed TB contact history was taken from 33 of the 66 XDR-TB patients 
who were admitted at BCH for initiation of XDR-TB. The total number of contacts 
among these 33 index patients was 55, (median, range) of 1.6 (1-5) contacts per 
patient. Of these contacts 16.4% (9/55) had drug susceptible TB, 60% (33/55) had 
MDR TB and 23.6% (13/55) XDR-TB. The vast majority (all except four) of the 
contacts were family members. In two cases the relationship to the patient was 
unknown and two contacts were prisoners both of whom had a diagnosis of XDR-
TB. 
 
3.3.7 Prisoners.  
Of the cohort of 174 XDR-TB patients, 55.7% (97/174) had a recorded prison 
history. 25.8% (25/97) had a history of incarceration. Eight patients 8.% (8/97) were 
under correctional service at the time of the history taking, and the remaining 
17.5% (17/97) had been previously incarcerated.  
 
3.3.8 Surgical outcomes 
Tarek Mohsen et al., in a seven year study of surgical interventions in Egypt, found 
that 34% of the patients had post operative complications with a mortality rate of 















1997 where we found 23% morbidity and 1.6% mortality rates. From these results 
we can see that post operative complication rates are acceptable and, overall 
mortality low. 
 
Of   135 XDR-TB patients assessed at a centre with thoracic surgery facilities 7.4% 
(10/135) were deemed suitable for possible surgery and referred for assessment by 
the cardio-thoracic surgeons. Of these 10 patients only three, all HIV-uninfected, 
underwent surgery (two undergoing pneumonectomies and one a lobectomy). Four 
patients refused surgery and three others were deemed unsuitable for surgery. Of 
those who underwent surgery, one patient converted and continued treatment but 
later relapsed. The other two patients died post-operatively at 12 and 24 days, 




Urgent implementation of rational control policies are required to counter the 
threat of XDR-TB. However, there are few data from Africa on which to base such 
recommendations, including those relevant to diagnosis, case finding, and 
treatment. We therefore attempted to address these issues using data gathered 

















We found that the median time for an XDR-TB patient to be started on treatment 
was 75 days, but patients could wait as long as 122 days (roughly four months) to 
initiate treatment.  Bonilla et al. reported that XDR-TB cases treated on the basis of 
DST results available within 31 days of starting treatment had much better 
outcomes then those XDR-TB patients whose DST results were only available after 
more than 30 days (Bonilla, 2008); however no reasons were given for this 
difference. In a study carried out in Hlabisa, KwaZulu-Natal, Heller et al. reported a 
median time from sputum acquisition to treatment start date of 84 days, in a 
community management programme, vs. 106.5 days in a hospital based treatment 
initiation model, some twenty-two and a half days earlier than the hospital-based 
cohort. This could possibly be due to delays in getting patients hospitalised due to 
unavailability of beds and the logistics of getting patients to the hospital. Culture-
conversion was also earlier in the community based programme (85 days vs. 119 
days) than in the more traditional hospital-based model. Therefore outcome 
results, particularly that of culture-conversion could be affected by the length of 
time a patient waits to be diagnosed, traced and initiated on treatment (Heller et 
al., 2010).  
 
The inordinately long time which patients and HCWs waiting for sputum results 
makes the use of rapid diagnostics crucial in reducing the time to diagnosis and 
treatment initiation in XDR-TB patients (Dowdy, Uys et al., 2009). Given that 
existing nucleic acid amplification tests perform less efficiently in smear-negative 















patients at first presentation to treatment facilities. A favourable cost benefit 
analysis of such an approach is supported by mathematical models (Dowdy). 
Alternative technologies that may perform well in smear-negative TB also require 
urgent development and validation (Migliori, 2008a, Pai M, 2006). Rapid diagnostic 
testing to second-line drugs need to be further developed and utilised (Ling DI, 
2008). 
 
An interesting finding in our study was that HIV uninfected patients had a longer 
delay than HIV-infected patients in initiating treatment. One possibility to account 
for these findings could be that patients attending HIV services are likely to be 
screened for TB earlier and sputum results carefully followed up. The possibility of 
survival and selection bias in explaining these results cannot be excluded.  
 
Given these results it is clear that a proportion 15-20% of XDR-TB is primary. We 
thus found, in terms of transmission dynamics, that genotypically 80% of the 
patients in our study had acquired XDR-TB.  Mlambo et al. also showed in a 
previous South- African-based study, that 26 out of the 41 XDR-TB patients 63% had 
a strain that was unique to the geographical settings from where the patients 
originated, suggesting acquisition of extensive drug resistance. Fifteen patients 
(37%) in this study, from five clinics/hospitals, showed isolates with clustered 















numbers of XDR-TB cases in South Africa. These findings, therefore, could be 
indicative of the early stages of an evolving epidemic (Mlambo, 2008). 
 
As part of his meta-analysis Sotgiu et al. found that the proportion of retreatment, 
in nine studies, was 49-98% in MDR-TB (higher in Tomsk (Russia), Peru and Korea 
than in Germany, Italy and in the four European countries study). The proportion of 
retreatment cases among XDR-TB was consistently higher at 75-100% (Sotgiu et al., 
2009). Similarly, in our studies over 70% of subjects had previous MDR-TB. This 
suggests, in keeping with the DNA fingerprinting data, that suboptimal treatment 
and drug management may have contributed to the amplification of drug 
resistance. There is an opportunity, therefore, to prevent further drug resistance 
through better clinical practises. Cognisance should therefore be paid to a patients 
TB history, patients with a history of previous MDR-TB should have a bolstered 
regimen and their clinical progress carefully monitored. In patients who are failing 
treatment, serious consideration should be given to stopping treatment to prevent 
amplification of drug resistance whereby strains could then be transmitted. 
 
The high capreomycin resistance in our study 58% is cause for concern since this 
antibiotic is the mainstay of regimens for the treatment of XDR tuberculosis that 
are used globally but not previously widely used in South Africa. The reasons for 
these high resistance rates are not known, but might partly indicate the unreliability 















aminoglycosides like kanamycin (Jugheli, 2005, Via et al., 2010). The high resistance 
rates to ethambutol, coupled with the fact that patients have already been exposed 
to this drug in regimens 1 and 2, were behind the rationale to change from 
ethambutol to terizidone in standardised MDR-TB regimens. 
 
Although we had small numbers of XDR-TB patients undergoing surgery in our study 
(three patients), other studies have demonstrated surgery to be a useful adjunct to 
chemotherapeutic treatment: Tarek Mohsen et al., in a seven-year study of surgical 
interventions on patients in Egypt, it was found that 34% had post operative 
complications with a mortality rate of 4.3%. These results compare very favourably 
to those in a study we conducted, in 1997, where we had 23% morbidity and 1.6% 
mortality rate. From these results we can see that post-operative complication 
rates are acceptable and overall mortality low (Van Leuven et al., 1997, Takeda et 
al., 2005) (Mohsen et al., 2007, Wang et al., 2008). 
 
 Sotgiu et al., in his systematic review reviewed seven studies, which reported on 
surgical outcomes. In two studies, better success rates were linked to surgery 
among XDR-TB patients (Kim et al., 2007, Mitnick et al., 2008, Chan et al., 2008, 
Eker et al., 2008, Kwon et al., 2008, Keshavjee et al., 2008). Thoracic resectional 
surgery (e.g. lobectomy or pneumonectomy) is an acceptable intervention given the 















localised and high-grade resistance present (Iseman et al., 1990). However, this 
strategy is not evidence based and the good outcomes may reflect selection bias. 
 
Our study found that, among those patients, where it was recorded, prison history 
among XDR-TB patients was high at 25.8% (25/97). In Russia TB rates in the 
penitentiary system are more than four-fold higher than in the general population 
(Academies, 2009). The nosocomial spread of tuberculosis in prisons to fellow 
prisoners and staff, as well as the spill over into the community when inmates are 
released, is of growing concern. Many prisoners have social and clinical risk factors 
for tuberculosis, which poses a challenge to TB control. The management of 
tuberculosis among prisoners is further complicated by high rates of loss to follow-
up care and poor treatment outcomes. 
 
 
In summary diagnosis of XDR-TB takes several weeks, treatment initiation after 
diagnosis is equally delayed, transmission of XDR-TB in the WC (2002 - 2008) is 
mainly acquired, rates of capreomycin resistance are high and primary transmission 
of XDR-TB in the community and prisons are an increasing concern as the epidemic 
evolves. These data call for: (i) rational control policies, to counter the XDR-TB 
threat including, (ii) infection control in congregate settings, (iii) appropriate 
treatment regimens for susceptible as well as MDR-TB, (iv) close monitoring of 
patients to prevent amplification of drug resistance, (v) introduction of community 















initiation of therapy. (vii) Rapid diagnostics (especially technologies for smear 
negative DR-TB, and susceptibility testing to second line drugs). (viii) Surgical 
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Figure 4.1    Kaplan-Meier probabilities of XDR-TB culture-conversion in patients 
whom received treatment for XDR-TB.       
A:  The whole cohort of patients receiving treatment 
 B:  HIV-infected and HIV-uninfected patients receiving treatment.  
Tables 
 Table 4.1     Number and percentage of patients with susceptible, multidrug- 
resistant versus extremely drug resistant-tuberculosis that smear and culture 
convert. (Horne et al., 2010) 
Table 4.2     Median days and range, where available to smear and culture-
conversion, in drug susceptible, multidrug-resistant versus extremely drug 















Table 4.3     Socio-demographic and clinical characteristics of XDR-TB patients who 
initiated treatment (n=174) comparing converters to non converters 
 
4.1          Introduction 
The success of a person’s anti-tuberculosis treatment is related to the 
bacteriological status while on treatment (Holtz et al., 2006).  In South Africa, as 
in many other resource limited countries, the diagnosis of first time tuberculosis 
is made primarily on sputum smear microscopy although many individuals are 
HIV co-infected and may be smear negative (2003). A culture is not performed 
for first time smear positive individuals.  
 
According to the WHO guidelines, following an initial positive smear if the 
sputum smear remains negative at subsequent testing during six months of 
treatment and there is clinical improvement, a sputum culture is not performed. 
If, however, the smear microscopy is positive at the end of the two-month 
intensive treatment phase, a culture with drug susceptibility testing should be 
requested. If drug resistance is present treatment should be altered 
appropriately. Sputum smear microscopy, culture and DST are also requested on 
those with suspected TB who have been previously treated for TB and in 
individuals at high risk for MDR TB including health care workers, contacts of 
MDR-TB patients and prisoners (WHO, 2006).  The rationale and validity of these 















CDC) includes sputum culture-conversion as one of the few follow-up measures 
for national TB surveillance (Holtz et al., 2006, dela Cruz). 
 
Previous WHO TB treatment guidelines have recommended the continuation of 
the intensive phase in newly treated TB patients if the two month smear is 
positive (WHO, 2003). There has, however, been a lack of evidence to support 
this. Horne (Horne et al., 2010) conducted a systematic review and meta-analysis 
to look at the accuracy of the sputum examination. In this Meta analysis both 
culture and smear had low positive predictive values (PPV) (9-18%) at two 
months and high negative predictive values (NPV) i.e. 93%. These findings 
suggested that it was improbable that sputum microbiology can correctly predict 
failure or relapse but that a negative sputum result makes relapse or failure 
unlikely (Horne et al., 2010). 
A summary of the two-month sputum smear and culture results from several 
studies included in Horne’s Meta analysis is shown in (Table 4.1). In smear 
positive TB (11 studies) the median percentage of two-month positive sputum 
was 13% range (3%-50%).  In those studies that looked at positive cultures 
(seven studies) the percentage was 17% with a range of (2%-63%). Another study 
conducted by Wang et al., showed a two-month sputum smear positivity rate of 







































Cao,  IJTLD 1998 2 56 (19%) 240 
(18%) 
-- -- 
Cao,  IJTLD 1998 3 12 (21%) 44 
(79%) 
-- -- 
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Tam,  IJTLD 2002 2 14 (8%) 158 
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14 (8%) 153 
(92%) 
Tam,  IJTLD 2002 3 6 (3%) 166 
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(98%) 














Wilkinson,  IJTLD 
1998 






















Table 4.1     Number and percentage of patients with susceptible, multidrug-resistant 
versus extensively drug resistant-tuberculosis who smear and culture convert (Horne et al., 
2010) 
 
In contrast to drug susceptible TB there are few studies looking at culture-
conversion amongst XDR-TB patients starting treatment in high burden areas. 
O’Donnell et al. reported very low conversion rates of 20% in KwaZulu-Natal (O 
Donnell  et al., 2009). These low rates of conversion might, however, be a reflection 
of the high TB burden together with the HIV epidemic and poor access to health 















are the factors underpinning this?  Holtz et al. found that in MDR-TB patients who 
did not convert were more likely to have a history of previous  
treatment for MDR-TB (29% vs. 11%; p=0.004), have a history of incarceration (45% 
vs. 26%; p= 0.003), and to be resistant to more drugs (6 vs. 5; p=0.008). 
In a systematic review undertaken by TBNET, Sotgiu et al. found that longer time to 
sputum conversion  was experienced in the majority  of the MDR and XDR-TB 
studies looked at (n=7). The median time to sputum culture-conversion in MDR-TB 
ranged from 58-99 days, while in XDR-TB this range was 60-195 days (Sotgiu et al., 
2009).  
 
In the cohorts that Horne used in his systematic review and meta-analysis, (shown 
below in Table 4.2) conversion of susceptible TB culture was 56.6 days. In MDR-TB 
the smear conversion median was days (range) 53.5(41-56), and culture-conversion 
61.2(56-98.5) days, which is similar to Sotgiu’s findings. In XDR-TB smear conversion 
occurred at 110(88-110) days and culture-conversion at 107.5 (52-195) days. 















Table 4.2: Median days and range, where available to smear and culture-conversion, in  
drug susceptible, multidrug-resistant versus extremely drug resistant-tuberculosis (Horne 
et al., 2010) 
 
Another important question, relates to the proportion of patients who convert 
but still have an unsuccessful treatment outcome. Holtz et al. documented “re-
conversion” in MDR-TB patients. These were patients who initially converted to 
sputum culture negative but subsequently reverted back to culture positive 11% 
(14/129). Median time for these patients to revert was 179 days with a range of 
70-746 days. Interestingly all except one of these patients “re-converted” back 
to negative, after between 2 and 7 positive cultures, and successfully completed 
treatment (Holtz et al., 2006). 
 
 Smear Culture Smear Culture Smear Culture 
Migliori, EID 
2007 
-- -- 41 56 110 97.5 
Migliori, ERJ 
2007 
-- -- 56 60 110 168 
Eker, EID -- -- 53.5 61.5 88 117 
Banerjee, CID 
2008 
-- -- -- 98.5 -- 195 



























Conversion also helps to define the definition for treatment failure, which 
hitherto, remains obscure in XDR-TB. Given the paucity of data about culture-
conversion related outcomes in XDR-TB we undertook a study to investigate the 
conversion rates among XDR-TB patients in four provinces/regions of South 
Africa. Furthermore we wanted to explore the factors contributing to a patient’s 
non-conversion or factors contributing to a delayed time to conversion. 
 
4.2          Methodology 
                4.2.1      Patients 
We retrospectively studied pulmonary XDR-TB patients diagnosed between 2002 
and 2008 in four provinces of South Africa (Western Cape, Eastern Cape, 
Northern Cape and Gauteng). Pulmonary XDR-TB was defined as a positive 
sputum culture for M. tuberculosis with in vitro resistance to at least: isoniazid, 
rifampicin, one of the second-line injectable agents (kanamycin, amikacin or 
capreomycin) and a fluoroquinolone. XDR-TB patients were hospitalised until 
sputum conversion and, at least in the Western Cape, patients were hospitalised 

















4.2.2      Bacteriological Examination 
XDR-TB patients had monthly sputum smear microscopy and culture; results 
were reported according to international standards (WHO, 1998). Both smear 
microscopy and culture were used to monitor patients throughout therapy 
(WHO, 2006).  
Up until 2006 all second-line testing was being done by the Lowenstein-Jensen 
on which growth of TB organisms is very slow. This method was phased out and 
has been replaced by one of the liquid medium Bactec systems. 
Culture and sensitivities were performed either by using Bactec MGIT 
(Mycobacteria Growth Indicator Tube) 960 fluorometric system (Sizwe and 
Gordonia) or the indirect proportion method on Middlebrooks 7H11 (Brooklyn 
and Jose Pearson). 
 
  4.2.3      Definitions 
In order for a patient to be considered culture and / or sputum smear positive 
at treatment initiation, the following criteria had to be met:  at least one positive 
pre-treatment culture taken less than 30 days before or within seven days after 
initiation of XDR-TB treatment (WHO, 2006).  In this XDR-TB study the definition 
used for the pre-treatment or “0” month sputum was a sputum sample that was 















Culture-conversion was defined as: two consecutively negative sputum cultures 
obtained 30 days apart, following proven culture positivity at treatment 
initiation.  Time to culture-conversion was calculated in days from treatment 
initiation until the date on which the first of two negative cultures was taken 
(Laserson et al., 2005). 
Patients who converted to sputum culture negative could also subsequently 
revert (i.e. become culture positive again). Date of reversion was calculated in 
days from the take date of the first of the two negative sputum’s (denoting 
culture-conversion), to the date on which the first positive culture thereafter 
was taken. 
 
4.2.4      Statistical Analysis 
A univariate Cox regression analysis (i.e. one predictor variable) was performed 
to look at predictor variables associated with culture-conversion versus no 
culture-conversion and the p values for comparison between groups evaluated 
by using the chi-square test or Fisher exact test. Statistical tests were two-sided 
and a p value less than 0.05 was considered statistically significant. Kaplan Meier 
curves were used for time to event analysis. Multivariate modelling was 



















                Converted 
n(%) 
Did not convert                      
n(%) 
       P 
      value 
    





141(81)   





    
HIV status     0.83 
      Positive 15(44.5) 67(47.5)   
     Negative 18(54.5) 74(52.5)   
    
Gender     0.47 
     Female 15(45.5) 67(47.5)   
     Male 18(54.5) 74(52.5)   
Smoking History 
 
     Yes 9(27.3) 40(28.4)   
     No 14(42.4) 35(24.8)   
     Unknown 10(30.3) 66(46.8)   
    
Previous MDR 
TB 
    
0.11 
     Yes 20(60.6) 105(74.5)   
     No 13(39.4) 36(25.5)   








    
Drugs used:       
     Ofloxacin                     7(21.2) 23(16.3) 0.50 
     
     Capreomycin  32(97.0) 130(92.2) 0.33 
                 
    
     Ethionamide  19(57.6) 86(61.0) 0.72 
     
     Ethambutol  14(42.4) 87(61.7) 0.40 
                
     PAS  32(97.0) 124(87.9) 0.13 
     
     Moxifloxacin  1(3.0) 13(9.2) 0.24 
                 
Table 4.3    Socio-demographic and clinical characteristics of XDR-TB patients who initiated 















4.3         Results 
Culture-conversion occurred in 19% (33/174) of patients who initiated treatment 
(Table 4.3) and this did not differ by HIV status, 45.5% (15/33) HIV-infected vs. 
54.5% (18/33) HIV-uninfected; p=0.57, (Figure 4.1 A and 4.1B). Of these 33 
patients, conversion occurred in 70%, 85% and 91% by 6, 9 and 12 months, 
respectively. Before the censor follow up date of 30 September 2008, 6% (2/33) 
of the XDR-TB patients who had converted had reverted back to culture 
positivity. Clinical and laboratory characteristics stratified by conversion status 
are shown in (Table 4.3).  
The number of days from the sputum acquisition (i.e. the date the sputum was 
taken) until the sputum report was 46 days (IQR 16.5-82.5), and from sputum 
report to treatment initiation a median of 20 days (IQR 5.5-39.8).  The length of 
time from sputum acquisition until the date XDR-TB treatment was initiated was 
significantly longer in converters versus non-converters [91(61-116) vs. 59 (43-
86); p= 0.001]. In addition low weight (<50kg) prior to treatment was associated 
with failure to convert (RR=3.31, 95%CI 1.08-10.1, p=0.04). 
Conversion rate was unaffected by gender, ethnicity or the number of prior 
MDR-TB episodes median (range) of 1 (1-2) in converters vs. non converters 1 (1-
2) for the number of MDR-TB episodes.   There was no significant difference in 
the duration of previous MDR median (IQR) in converters vs. non-converters 9 
(6-14) vs. 6 (4-10) months respectively, (p= 0.37) and similarly, the median (IQR) 
number of prior drug susceptible TB episodes converters 1(1-2vs. non-converters 















Figure 4.1    Kaplan-Meier probabilities of XDR-TB culture-conversion in patients whom 
received treatment for XDR-TB. 
A     whole cohort of patients receiving treatment 
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Overall culture-conversion rates for sputum positive XDR-TB patients were 
disappointingly low at 19% (33/174). These rates are, however, similar to those 
documented by O’Donnell et al., whose study in KwaZulu-Natal, showed culture-
conversion rates of 20% (12/60). Results from four studies in intermediate or 
high-burden settings with smaller cohorts had better culture-conversion 
rates than those found in this study (Mitnick et al., 2008, Kwon et al., 2008, 
Keshavjee et al., 2008, Kim et al., 2008, O Donnell  et al., 2009). Mitnick and 
colleagues, in Peru, showed much higher conversion rates among XDR-TB 
patients, 67% (32/48) of patients with XDR-TB had converted by four months 
(median time to culture-conversion 90 days). In this study moxifloxacin, a newer 
generation fluoroquinolone, formed a standard part of the treatment regimen 
(Jacobson, 2010). In our study very few subjects received a fluoroquinolone, 
which could be one of the reasons for our poor conversion rates. 
Determining the length of time to sputum culture-conversion assists programme 
managers in defining when patients could be considered treatment failures. In 
this study 85% of patients had converted by month 9 and only 6% (2/33) further 
patients converted thereafter. Thus patients can be considered a treatment 
failure after 12 months of adherent and observed treatment. Based on DOTs-
plus data and reaffirmed in our study findings this definition is now being used in 















 Holtz et al. has previously shown that culture-conversion is a valuable interim 
measure to evaluate patient progress (Holtz et al., 2006). He showed that 
patients who convert before two months had better treatment related 
outcomes. Although we did not find this in our study, Holtz et al. found that 
previous MDR treatment was a predictor for delayed culture-conversion. A 
reason for this could be that patients with previous MDR-TB treatment have 
been treated for a longer time period have more extensive bilateral disease and 
have a lower body weight (Holtz et al., 2006). Our data supports this with the 
univariate regression analysis showing a relative risk of failure to convert of 3.3% 
in those with low body weight at treatment initiation. We were not able in this 
retrospective review to accurately document the extent of disease on chest X-
ray (CXR).  
 
HIV status did not affect culture-conversion rates with approximately 50 percent 
of both HIV positive and HIV negative patients converting to sputum culture 
negative.  O’Donnell et al. also found that HIV status was not a predictor of 
culture-conversion in KwaZulu-Natal (O Donnell  et al., 2009).  ………….Given the 
experience of the Tugela Ferry outbreak and high mortality rates in severely 
immune-compromised individuals it is conceivable that HIV positive subjects 
with severe disease may have died before diagnosis. In addition HIV status did 
not affect survival in this study and thus only the relatively immune intact HIV 















in keeping with those in drug susceptible patients where culture-conversion is 
independent of HIV status (Senkoro et al., 2010, Bwire et al., 1999). 
 
Culture reversion occurred in 6% (2/13) but by the end of the study and at the 
time of writing a further four patients had reverted to sputum culture positive 
54% (7/13). The reasons why patients convert and then revert back to culture 
positivity needs to be explored. Possible reasons could include the stopping of 
capreomycin, because at the time of discharge from hospital following sputum 
conversion capreomycin is stopped.  In addition due to the high pill burden 
adherence is likely to be poorer in the outpatient compared to in hospital 
treatment administration. Poor sterilising ability of XDR TB drugs and residual 
disease not communicating with the airways may give false indications of 
conversion by sputum culture.  Ongoing mycobacterial replication and 
subsequent erosion into airways may thus result in reversions.   
 
Early diagnosis and initiation of XDR-TB treatment, particularly in patients in 
whom we can predict a longer time to culture-conversion and poorer treatment 
outcomes, is crucial. In this study the average length of time from sputum 
acquisition to treatment initiation was 75 days (IQR 43-116). However, delay in 
treatment initiation of nearly four months is unacceptable. It is imperative that 
the time to treatment initiation be reduced as it may lead to poor conversion 















tests will undoubtedly reduce the time to diagnosis of XDR-TB. However, even 
then the performance of the Hain MDR-TBplus assay is suboptimal in smear 
negative compared with smear positive patients. As many of the patients in this 
study were smear negative, better polymerase chain reaction (PCR) based tests 
will be required. The performance of the Hain-SL version remains to be 
evaluated in clinical samples and in smear negative TB. If rapid diagnostics are 
coupled to good clinic and laboratory infrastructure along with prompt 
communication of results, time to initiation of therapy is likely to be reduced. 
The ultimate effect on treatment outcomes remains to be seen.  
 
There are several limitations to this study inherent to its retrospective nature 
(outlined in the last chapter and restated here; furthermore, several of these 
limitations will apply to subsequent chapters). We tried to limit bias by excluding 
from the analysis, patients with incomplete treatment and microbiological data, 
subjects whose sputum culture status was unknown at treatment initiation, and 
cross-checking patients against clinical and laboratory databases. Given that all 
cases of XDR-TB were detected passively, it is likely that several cases were not 
documented. This is due to patients remaining undiagnosed, dying prior to 
susceptibility testing, not accessing health care, or in whom appropriate 
susceptibility-testing was not undertaken due to capacity limitations. Although 
this would not alter the conversion rates of those on treatment it would impact 
on the total cases of XDR-TB in the country. Another limitation is that our study 















cure. However, as capreomycin-based regimes and second-line DST only became 
widely available in several South- African centres in 2007 these data are not yet 
available. Nevertheless, our study did encompass mortality data and culture-
conversion which correlates well with late treatment outcomes in drug-resistant 
TB (Holtz et al., 2006).  
 
 XDR-TB patients who have a low body weight at diagnosis may well benefit from 
intensive nutritional support (e.g. high protein diets, meal supplements and 
vitamins) and close monitoring of treatment response.  Newer rapid diagnostic 
methods, with appropriate infrastructural and communication support, need to 
be implemented to reduce the time taken for culture-conversion and DST results 
to be available to managing clinicians. This will in turn allow for earlier treatment 
initiation or modification with a better chance for a successful treatment 
outcome. Given the poor treatment outcomes in XDR-TB aggressive preventative 
measures to limit the creation of MDR-TB and XDR-TB must be taken, and new 

















Chapter 5:  Mortality 
 5.1 Introduction 
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Figure 5.1:  Kaplan-Meier probabilities of death 
(A) Those who died before treatment initiation stratified by HIV status 
(B) The whole cohort of patients from the date of treatment-initiation 
(C) HIV-infected and HIV-uninfected patients receiving treatment from date of 
treatment-initiation 
(D) In HIV-infected patients receiving treatment stratified by HAART use 
(E) HIV-infected and HIV-uninfected patients receiving treatment from date of 
treatment-initiation 
(F) In HIV-infected patients receiving treatment stratified by HAART use 
 
Tables 
Table 5.1: Mortality in XDR-TB patients who initiated treatment   (n=174) stratified by 
















Table 5.2: Cox proportional hazards regression model of factors associated with risk 
of death in all patients receiving XDR-TB treatment (n=174) (2-A), and in HIV-
infected patients only (2B).  
 
5.1 Introduction 
Tuberculosis kills an estimated 1.3 million people per year worldwide, with an 
estimated 150 000 from MDR-TB (WHO, 2010).  In 2008 the number of cases of 
MDR-TB in Africa (primary and acquired) was estimated at 69 000, ~ 30% of the 
global estimate, with an estimated annual mortality of 22 000 cases. This mortality 
rate may in fact be higher as in many parts of Africa where laboratory facilities are 
limited and many cases may never be diagnosed or adequately treated with 
second-line drugs. This makes accurate mortality rates due to MDR-TB challenging. 
In South Africa the number of MDR-TB cases was estimated at 13 000 cases in 2008 
(WHO, 2010). 
 
In case-based surveillance data from over 40 000 TB patients treated in 17 
European Union countries MDR was strongly associated with the risk of dying from 
any cause (adjusted OR=3.9, 95% CI 3.3–4.6). This surveillance although it had many 
limitations, showed that drug resistance was an important risk for death among TB 
patients even in developed countries (WHO, 2010).   
 
However, there are few data about XDR-TB mortality globally and in Africa. The first 















Africa was the Tugela Ferry XDR-TB outbreak reported in 2006. In this hospital-
acquired XDR-TB outbreak involving 53 XDR-TB patients there was an almost 100% 
mortality with the average time to death of 14 days (Gandhi et al., 2010). Although 
these patients had not received XDR-TB treatment and hardly any Highly active 
anti-retroviral therapy (HAART), this news was received with shock by the global 
community and set a precedent for just what TB control programmes could expect 
from efforts to treat this highly resistant form of tuberculosis (Mitnick et al., 2008). 
Other studies have also described the scenario of untreatable strains of 
tuberculosis (Chauhan, 2007, Masjedi et al., 2006). 
 
Thus, a widely held perception was that XDR-TB in Africa occurs predominantly in 
HIV positive patients who are more susceptible to infection and whose survival is 
dismal. It has however been shown that XDR-TB existed in South Africa prior to this 
outbreak in most provinces, with 4% of MDR-TB cases in fact being undiagnosed 
XDR-TB cases (Mlambo, 2008). 
 
In another study in KwaZulu-Natal, Gandhi et al. showed extremely high death rates 
from MDR and XDR-TB, particularly in the first 30 days after sputum acquisition, 
when 40% of MDR and 51% of XDR-TB cases died. The one year mortality in this 
study was 71% for MDR and 83% for XDR-TB with HIV rates of 90% in both the MDR 
and XDR groups (Gandhi et al., 2006b).  It is likely that HIV co-infection in MDR and 















In a study conducted by Mitnick et al. (Mitnick et al., 2008)in Peru, 0.2% (7/651) of 
patients died before treatment could be initiated. 14.3% (1/7) of these patients 
were XDR, and 85.7% (6/7) were MDR. None of these patients were HIV-infected. 
The hazard ratio for death in XDR-TB patients as compared to MDR was 1.1% (95% 
CI, 0.59 to 2.02, p=0.79) and the death rate was 10%. MDR mortality rates were 
higher but the risk of death did not differ significantly between the two groups of 
patients 22.9% (11/48) in XDR-TB and 20.4% (123/603). Although causes of death 
were unknown, more drug exposure was associated with the risk of death in this 
study. 
 
The large numbers of people who die soon after sputum collection and before 
treatment initiation highlights the importance of timely diagnosis of resistant TB 
and early initiation of effective anti-tuberculosis treatment and antiretrovirals (ART) 
(ARVs) in co-infected patients. (Gandhi et al., 2006a) In a systematic review and 
meta-analysis on XDR-TB outcomes the summary estimate of patients who died 
was 20.8% (95% CI, 14.2%-27.35). This was higher than the death rates reported for 
MDR-TB providing further proof of the higher mortality of those patients with XDR-
TB (Jacobson, 2010). 
 
Despite having the highest TB caseloads there have been relatively few XDR-TB 
cases identified from high burden settings, including those with a high HIV 















remains largely unknown. It also remains unclear whether a similar mortality rate 
was prevalent in other South- African provinces where different strains and 
predictors of outcomes were prevalent. To address these questions we evaluated 
mortality in XDR-TB patients recruited from four provinces, other than KwaZulu-




A total of 227 patients diagnosed with XDR-TB were identified. Twenty eight were 
excluded: (two children under the age of 18, eight participants with unknown 
sputum culture results at XDR-TB treatment initiation, one patient who was 
transferred from the Eastern Cape to the Western Cape, four patients whom had 
incomplete data and 13 without a documented HIV status.)  Of the remaining 199 
XDR-TB patients 174 patients initiated treatment for XDR-TB, 21 who died before 
treatment initiation and four in whom XDR-TB treatment was never initiated.  
 
5.2.2 Definition  
The definition of death, adapted from that defining MDR-TB mortality, was based 
on that used by Laserson et al. “an XDR-TB patient who died for any reason during 
the course of XDR-TB treatment” (Laserson et al., 2005) . 















A univariate Cox regression analysis (i.e. one predictor variable) was performed to 
look at predictor variables associated with death versus no death and the p values 
for comparison between groups evaluated by using the chi-square test, or Fisher 
exact test. Statistical tests were two-sided and a p value less than 0.05 was 
considered statistically significant. Kaplan Meier curves were used for time to event 
analysis, both from the time of diagnosis and that of treatment. No multivariate 
model was conducted owing to lack of association in the univariate models 
performed. Cox proportional hazards regression models were fitted to determine 
risk factors associated with outcomes in a time-to-event based analyses. Variables 
found to be significantly associated with the outcome (p<0.05) were included in the 
final model. The proportionality assumption of th  Cox models was tested using –
ln[–ln (survival)] curves and regression of scaled Schoenfeld residuals on functions 
of time. The assumption of uninformative censoring (i.e. more censored 
observations at an earlier time in one group compared to another or a greater 
proportion of censored survival times in patients with a particular range of values of 
the explanatory variables) was examined by plotting observed survival times against 


















In total 42.2% (84/199) of the XDR-TB patients died during a median follow-up 
period of   6.9 (3.1-12.0) months. 10.5% (21/199) patients died before treatment 
was initiated. Overall and treatment-initiated one year mortality rates were 42% 
(84/199) and 36% (62/174), respectively (Figure 5.1D and Table 5.1); 33, 3% (28/84) 
of all deaths occurred before treatment initiation (figure 5.1C). Of the total of 174 
subjects who initiated treatment, the mortality rate was 41.5 % (34/82) in HIV 





















Total number of 
patients 112(64.4) 62(35.6)  
Age, median(IQR) 32.1(25.8-42.8) 37.2(28.5-47.1) 0.07 
HIV status   0.13 
      Positive 48(42.9) 34(54.8)  
     Negative 64(57.1) 28(45.2)  
Gender   0.59 
     Female 59(52.7) 30(48.4)  
     Male 53(47.3) 32(51.6)  
Smoking History   0.004 
     Yes 39(34.8) 10(16.1)  
     No 34(30.4) 15(24.2)  
     Unknown 39(34.8) 37(59.7)  
Previous MDR TB   <0.0001 
     Yes 70(62.5) 55(88.7)  
     No 42(37.5) 7(11.3)  
Weight(kg), 
median (IQR), 
(n=65) 50.0(44.0 – 60.0) 44.0(39.0–49.0) 0.004 
Drugs used     
     Ofloxacin    0.02 
           Yes 25(22.3) 5(8.1)  
           No 87(77.7) 57(91.9)  
     Capreomycin    0.43 
           Yes 103(92.0) 58(95.8)  
           No 9(8.0) 3(4.8)  
     Ethionamide    0.61 
           Yes 66(58.9) 39(62.9)  
           No 46(41.1) 23(37.1)  
     Ethambutol    0.01 
           Yes 57(50.9) 44(71.0)  
           No 55(49.1) 18(29.0)  
     PAS    0.41 
           Yes 102(91.1) 54(87.1)  
           No 10(8.9) 8(12.9)  
     Moxifloxacin    0.02 
           Yes 13(11.6) 1(1.6)  
           No 99(88.4) 61(98.4)  
  
Table 5.1: Mortality in XDR-TB patients who initiated treatment   (n=174) stratified by 
















Of the deaths prior to treatment initiation 75% (21/28) died before a diagnosis of 
XDR-TB had been made (i.e. during the lapse of time between sputum acquisition 
date and sputum report date or time to trace the patient once the result was 
known). By contrast, 25% (7/28) of deaths occurred in patients waiting for a bed at 
the XDR-TB facility or shortly after admission but before treatment could be 
commenced. In 4 patients it was decided, on admission to the XDR-TB treatment 
facility, that the patient’s clinical condition was so poor it precluded them from 
XDR-TB treatment initiation. 
 
Demographic variables which were stratified by mortality are shown in Table 1. 
There was no difference in the number of deaths (p>0.05) when these outcomes 
were stratified by sex, ethnic origin, and the number of previous episodes of MDR 
tuberculosis (median 1 episode [1–1] each in those who survived and died, 1 
episode [1–2]. There was no significant difference in the duration of previous 
treatment for MDR tuberculosis in patients who survived versus those who died 
(median 8.0 months [5.0–12.0] vs. 5.5 months [4–8], respectively; p=0.7). Similarly, 
the median number of previous drug-susceptible episodes of tuberculosis in the 
same groups was not different (survivors vs. non-survivors: 1 [1–2] vs. 1 [1–2], 
respectively, p=0.1 vs. 1 [1–2], respectively, p=0.2). The time from sputum 
acquisition to start of treatment was significantly longer in those who survived than 
















There was no significant difference in the median (IQR) duration (months) of prior 
MDR treatment in those that survived versus those that died [8 (5-12) vs. 5.5 (4 -8); 
p=0.7]. Similarly, the median number of prior drug susceptible episodes of TB was 
no different in the same groups (2 vs. 2; p=0.1 and 2 vs. 2; p=0.2, respectively).  
 
The length of time from sputum acquisition (i.e. the date the sputum was taken) 
until the date XDR-TB treatment was initiated was significantly longer in those who 
survived versus those who died [78 (53-107) days vs.  57 (36-67) days; p= 0.001]. 
The median duration of follow-up from treatment initiation to event (death, loss to 
follow-up or the censor date) was 6.9 months (IQR 3.1 to 12.0). The median (IQR) 
time (days) from sputum acquisition to treatment initiation was significantly longer 
in those who survived versus those who died [78 (53-107) vs. 57 (36-67); p=0.001].  
The results were similar when survival was calculated from diagnosis rather than 
treatment initiation date and outcomes were similar prior to and after March 2007 
when capreomycin and PAS were introduced into the programme.  
 
It was not possible to ascertain the cause of death but in those who died prior to 
treatment initiation HIV-infected patients had a significantly higher mortality in the 
time to event analysis compared to HIV-uninfected patients (Figure 5.1C).  174 (82 
HIV-infected and 92 HIV-uninfected) received treatment. Of these 36% (62/174) 















uninfected patients were not significantly different: [(34/82(41.5%) vs. 28/9(30.4%); 
p=0.13)] (Table 5.1 and Figure 5.1E) 
 
In the sub-analysis conducted in HIV-infected patients, only HAART and 
moxifloxacin usage were independent predictors of survival (Table 5.2B). Mortality 
was significantly lower in HIV-infected individuals who received HAART compared 
to those who did not (adjusted risk ratio= 0.31, 95% CI 0.15-0.61, p=0.01) and 12 
month mortality was 26% vs. 76%, p=0.02 in the same groups; (Figure 5.1F; Table 
5.2B). Survival did not differ by CD4 count but the analysis was based upon a small 
number of participants with verifiable CD4 counts specifically at the time of 































Univariate analysis Multivariate analysis 
Odds Ratio (95%CI) P-value* Odds Ratio (95%CI) P-value 
Isoniazid          0.20(0.08-0.49) < 0.0001       0.76(0.24-2.51) 0.68 
Moxifloxacin 0.12(0.02-0.89) 0.03 0.11(0.01-0.82) 0.03 
Ethambutol 1.87(1.08-3.26) 0.03 1.49(0.69-3.23) 0.31 
Dapsone 2.19(1.25-3.84) 0.006 1.79(0.84-3.85) 0.13 
Clofazamine 0.30(0.11-0.82) 0.02 0.54(0.14-2.08) 0.37 
Clarithromycin 0.55(0.32-0.94) 0.03 1.46(0.61-3.52) 0.40 
Terizidone 0.48(0.27-0.84)                                       0.01 1.35(0.71-2.55) 0.37 
Number of drugs used 0.74(0.61-0.88) 0.001 0.59(0.45-0.78) <0.0001 





Univariate analysis Multivariate analysis 
Odds Ratio (95%CI) P-value
*
 Odds Ratio (95%CI) P-value 
HAART  0.31(0.15-0.61) 0.001 0.38(0.18-0.80) 0.01 
Isoniazid             0.17(0.05-0.56) 0.005 0.41(0.06-2.96) 0.39 
Moxifloxacin 13(0.02-0.92) 0.006 0.08(0.01-0.61) 0.02 
PZA 4.1(1.00-17.5) 0.04 3.48(0.74-16.5) 0.12 
Clofazamine 0.21(0.05-0.86) 0.03 1.37(0.14-13.82)                                       0.79
Previous MDR treatment 7.46(1.79-31.2) 0.006 4.50(0.83-24.4) 0.08 
Number of drugs used 0.74(0.56-99) 0.04 0.87(0.58-1.26) 0.43 
 
Table 5.2: Cox proportional hazards regression model of factors associated with risk of 
death in all patients receiving XDR-TB treatment (n=174) (2-A), and in HIV-infected patients 




















Figure 5.1:  Kaplan-Meier probabilities of death: 
(A ) Probabilities of culture conversion in patients with and without HIV infection given 
treatment 
(B) Probabilities of death in patients who died before initiation of treatment stratified by 
HIV status 
 (C) Probabilities of death in patients with and without HIV infection given treatment from 
date of treatment initiation 
 (D) Probabilities of death in patients with HIV infection given treatment stratified 

















Available XDR-TB-related data from Africa indicate that in a setting of probable 
nosocomial transmission XDR-TB almost 100% of patients were HIV-infected and 
died at a median of two weeks after treatment initiation (Gandhi et al., 2006b). By 
contrast, our study showed that a large proportion of XDR-TB patients were HIV-
uninfected and that there is no difference in mortality rates when comparing HIV-
infected versus HIV non-infected individuals. Furthermore, O’Donnell et al. found in 
his study at King George V hospital in Durban, KwaZulu-Natal that HIV status did not 
predict death or culture-conversion (O Donnell  et al., 2009).  
 
Moreover, we have shown that survival in African XDR-TB HIV co-infected patients 
recruited from a wider setting is substantially longer (12 month mortality of 42%) 
than previously recognised. It has also shown for the first time that HAART, despite 
its overlapping toxicity and side effects with anti-TB drugs and the high pill burden, 
substantially improves survival in HIV positive patients and was generally well 
tolerated. O’Donnell et al. demonstrated a trend towards better survival in HIV-
infected patients with CD4 counts less than 200 cellss/mm3 on HAART compared to 
those not on HAART (OR 0.094,95% CI 0.007-1.22)  (O Donnell  et al., 2009). Our 
data suggests that HAART should be used at an early stage in all co-infected 
















A key finding of this retrospective case note review was that overall prognosis was 
poor regardless of HIV status despite supervised in-patient multi-drug treatment; 
and access, when available, to surgical resection of diseased lung.  Possible reasons 
for the poorer survival seen in this cohort compared with that seen in the meta 
analysis  conducted by Jacobson et al. (Jacobson, 2010) may include the long 
duration of previous drug-resistant TB and the predominantly non moxifloxacin 
containing regimens used. The national TB programme, at least in the Western 
Cape, had not as yet released moxifloxacin for use in XDR-TB regimens at the time 
of this study.  
 
Nevertheless, mortality rates did not differ in centres with a high urbanised 
population and easy medical access (Gauteng and Western Cape) compared with 
more rural populations with limited access (Eastern Cape and Northern Cape). 
Although we found a survival benefit in moxifloxacin-treated patients, we could not 
correlate this to quinolone-specific resistance profiles because of the lack of specific 
DST data. It should also be emphasised that our findings are only generalisable to a 
resource-poor high HIV prevalence setting like South Africa. Outcomes in low HIV 
prevalence settings and those in even more severely resource-constrained settings 

















HIV-infected XDR-TB patients treated with appropriate anti-TB regimens together 
with HAART had a lower mortality than in those who were treated with appropriate 
TB treatment but not started on HAART and thus survival in HIV-infected patients is 
better than that previously reported (Gandhi et al., 2009).  
 
There are several limitations of our study (in addition to those already mentioned in 
the previous chapter). The WHO definition of death is any death during treatment 
and does not take into account patients dying after treatment failure or 
interruption. Furthermore, deaths in our study were not categorised into causes of 
death due to drug resistant TB or other causes. Selection bias, particularly in the 
HIV-infected sub-group, may have led to an underestimate of the true mortality as 
survivors would have been more likely to have been included in our study. 
In summary, given the currently available diagnostic tools, case finding strategies, 
available resources and co-morbidities, treatment-related outcomes in patients 
with XDR-TB in South Africa are poor. Death rates from XDR-TB are high but not 
necessarily linked to HIV infection as has been suggested by studies from KwaZulu-
Natal. Nevertheless the addition of moxifloxacin to regimens can reduce mortality. 
Studies examining the efficacy of newer generation fluoroquinolones are now 
urgently needed.  
 
Furthermore, survival in HIV co-infected subjects is better than previously reported 















is now needed to identify M/XDR-TB cases early and before they transmit disease. 
Rapid diagnostics and early initiation of treatment and ART, regardless of CD4 
counts are imperative for better treatment outcomes. Community-based M/XDR-TB 
models are also need to be explored to reduce the risk of nosocomial transmission 
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Figure 6.1     Study plan stratified according to treatment site, HIV status and 
severity of adverse    drug reactions. 
Figure 6.2    Kaplan-Meier probabilities of XDR-TB culture-conversion in: (A) 
The whole cohort  of patients who experienced ADRs stratified by severity 
score i.e. none or mild to moderate (grade 0, 1 and 2), and severe (grade 3 to 
5); (B) HIV-infected patients whom experienced ADRs stratified by stratified 
by severity score; (C) HIV-uninfected patients who experienced ADRs 
stratified by stratified by severity score, and  Kaplan-Meier probabilities of 
death: (D) The whole cohort of patients from the date of treatment-initiation, 
(E) HIV-infected patients who experienced ADRs stratified by severity score, 




Table 6.1     Definitions used to grade, identify and classify adverse drug 
reactions 
Table 6.2     Socio-demographic and clinical characteristics of 115 patients 
who initiated treatment for extensively drug-resistant tuberculosis (XDR-TB) 
Table 6.3     Individualised regimens prescribed for 115 Patients with XDR-TB 
stratified by duration of treatment, severity of the ADR, and drug resistance 
profiles.  























6.1      Introduction 
Over the last two decades the entity multi-drug resistant tuberculosis (MDR-TB i.e. 
resistance to at least isoniazid and rifampicin) has emerged. In 2008 there were 
approximately 450 000 cases of MDR-TB globally.     Between 5 to 10% of MDR-TB 
cases are thought to be due to extensively drug resistant tuberculosis (XDR-TB i.e. 
resistance to rifampicin, isoniazid, fluoroquinolones and one of the 2nd line 
injectable agents i.e. kanamycin, amikacin or capreomycin). MDR-TB and XDR-TB 
now threaten to destabilise TB control in several regions of the world including 
Africa, Eastern Europe, Russia, central Asia, India and China (Dheda et al., 2010b).   
            
In high burden settings treatment outcomes of MDR-TB are disappointing with only 
~50% of patient’s successfully completing treatment (Shean et al., 2008). Outcomes 
in XDR-TB are poorer. We and others have recently shown that, in contrast to low 
and intermediate burden settings (Mitnick et al., 2008), less that 20% of patients 
with XDR-TB culture-convert in high burden settings (Migliori et al., 2008, Dheda et 
al., 2010b). Treatment options, because of the high grade of drug resistance are 
severely limited and the higher the total number of appropriate drugs used in a 
regimen the better the outcome(Dheda et al., 2010b). Thus, treatment interruption 
due to any cause may potentially subvert successful outcome in patients with XDR-
TB. Failure to identify and manage adverse drug reactions (ADRs) may also have 
serious implications for patient perceptions about toxicity versus benefit, and thus 















recently shown that (ADRs) are common in patients with XDR-TB (Dheda et al., 
2010b, O Donnell  et al., 2009). 
 
However, data about whether ADRs impact on treatment-related outcomes in 
patients with drug-resistant TB are scarce. It is also unclear how the M. tuberculosis 
strain phenotype and host factors such as HIV co-infection impact on the frequency 
and severity of ADRs, and associated clinical outcomes. Given that capreomycin 
modulates outcomes and is a vital backbone of most XDR-TB treatment regimens 
(Migliori, 2008b), the frequency of ADRs to capreomycin and their temporal 
relationship to treatment initiation are of interest. Collectively, these data can 
inform on several aspects of management including the design and monitoring of 
treatment regimens for XDR-TB and formulating strategies to prevent treatment 
interruption, thus facilitating compliance and minimising treatment failure. To 
address these gaps in our knowledge and, in particular, to evaluate the impact of 
ADRs on outcomes we reviewed the case records of 115 patients treated for XDR-
TB at three treatment centres in South Africa. 
 
6.2    Methodology 
 
6.2.1    Study setting and participants 
We retrospectively reviewed the case records of 115 laboratory-confirmed XDR-TB 
patients diagnosed between August 2002 and February 2008 at three designated 
XDR-TB treatment centres in South Africa (see Figure 6.1 for the study outline). 















(duration, type and severity), regimen used (dose, indication, route of 
administration), culture-conversion and mortality outcomes, and HIV status. 
Associated demographic and clinical information were also captured. Ethical 
approval was obtained from the University of Cape Town, and the University of 
Witwatersrand‘s human research ethics committees. 
 
6.2.2     Diagnosis of XDR-TB 
From 2002 sputum culture and susceptibility testing for second-line agents, 
amikacin, ofloxacin, and ethionamide was performed as previously described 
(Dheda et al., 2010a). Isolates of M. tuberculosis that were resistant at diagnosis 
(time of sputum collection) to at least isoniazid, rifampicin, a fluoroquinolone, and 
at least one of the second-line injectable drugs (amikacin, kanamycin, or 
capreomycin) were judged to be XDR-TB. Drug-susceptibility testing to 
capreomycin, cycloserine, terizidone (a derivative containing a double molecule of 
cycloserine), and fluoroquinolones other than ofloxacin was unavailable within the 
provincial laboratories.  
 
6.2.3    Treatment regimens 
XDR-TB treatment was only initiated and administered in hospital with the use of 
capreomycin and para-aminosalycilic acid (PAS) as the anchor drugs, which became 
available in South Africa in late 2006 / early 2007. The drugs used in the treatment 















amoxicillin/clavulanate and azithromycin) were used at the discretion of the 
attending clinician and those to which the organism demonstrated susceptibility. 
High-dose INH was administered at a dose of 10mg/kg. Linezolid was unavailable 
through the National TB Programme and clofazimine and moxifloxacin was used in 
selected centres on a limited basis. HAART was offered to all HIV co-infected 































Figure 6.1     Study plan stratified according to treatment site, HIV status and severity 
of adverse drug reactions. 



























































































































6.2.4    Definition of adverse drug reactions 
ADRs were defined as unintended adverse responses occurring at therapeutic 
doses resulting in either death, drug withdrawal, change in the administration 
of the frequency or dose of the drug, or, no action being taken  (Guidelines). 
These were graded according to the modified American National Institute of 
Health (common terminology criteria for adverse events [CTCAE]. For the 
purposes of analysis grades 1 and 2 ADRs were considered mild to moderate 
and grade 3 to 5 severe. Multiple events of the same ADR were counted 
separately. The definitions used to identify and classify adverse drug reactions 


















A. Grading of Adverse drug reactions
1
 
grade 0   no ADR  
grade 1  mild adverse event i.e. described in the patient’s 
management records but no action was taken 
grade 2  moderate ADR resulting in either changing the dose or 
frequency of the offending drug or another drug(s) was 
added to manage the adverse event  
grade 3  the side effect was severe enough for the offending 
drug to be stopped  
grade 4 the ADR was life threatening or disabling  
 grade 5  the adverse event caused the death of the patient 
 
B. Definitions used to identify and classify adverse drug reactions.  
Nausea, vomiting, diarrhoea.  
Other GI symptoms: abdominal pain, 
dyspepsia, epigastric discomfort and 
cramps  






Sore tongue / throat  
Generalised itchiness  
Fatigue  
Numbness of extremities  Symptoms and findings consistent with neuropathy, e.g. 
pain or numbness of the distal extremities diagnosed by 
a physician.  
Skin reaction  A  dermatological reaction felt to be related to anti-
tuberculosis medications as documented by the 
physician or  dermatologist  
Hypokalemia  < 3.5  meq/L (normal range: 3.5 - 5.5 meq/L)                   
Hypothroidism  At least one thyroid stimulating hormone(TSH) result 
>4.94 IU/ml (normal 0.35 - 4.94)  
Depression/psychosis  As diagnosed by the TB physician and/ or psychiatrist, 





Visual disturbance  Diagnosed by the physician / eye specialist as being 
related to the TB drugs  
Arthralgia  Painful joints as reported by patient and documented 
by physician or nurse  
Ototoxicity  Hearing loss confirmed by audiometry and/or physical 
examination  
Renal impairment /renal failure  Creatinine > 100  µmol/L  
Hepatotoxicity  Raised bilirubin or elevated transaminases > 3 times the 
upper limit of normal, and ascribable to a specific drug  
1
These were graded according to the modified American National Institute of Health common 
terminology criteria for   adverse events [CTCAE]  
 
















6.2.5    Outcomes 
The date of diagnosis of XDR-TB was taken as the date on which the sputum 
sample was taken, and from which the organism was cultured. Conversion 
was judged to have occurred when two consecutively negative cultures were 
obtained, one month apart, and providing that a culture taken at initiation of 
XDR-TB treatment was positive.  
 
  6.2.6    Mycobacterium tuberculosis strain typing  
A subset of 53 XDR-TB isolates from patients from the Western Cape were 
genotyped by IS6110 DNA fingerprinting (Warren, 2006) spoligotyping 
(Kamerbeek, 1997). Strains were categorised as Beijing or non-Beijing 
according their spoligotype signature {STREICHER, 2007 #1588}. 
 
  6.2.7    Data handling and statistical analysis 
Refer to methodologyin the other chapters 
 
 
6.3    Results 
  6.3.1     Demographic and clinical characteristics 
ADR’s were reported in 58% (67/115) of patients.  The breakdown by severity 
of ADR and HIV status, stratified by patient number and total number of 
ADRs, is shown in Figure 1. We could not identify any demographic and 















ADRs (grade 1 to 5) compared to those who did not develop an ADR (grade 0). 
We then evaluated demographic and clinical characteristics stratified by the 
severity of ADRs (group 0, 1 and 2 vs. group 3, 4, and 5; outlined in Table 6.2). 
Patients with severe ADRs (grade 3 to 5), when compared to those with mild, 
moderate or no ADRs (grade 0, 1 and 2), were more likely to be female, have 
had previous MDR-TB or drug susceptible TB, and had fewer drugs in their 
treatment regimens (Table 6.2). In the multivariate analysis only a history of 
previous MDR-TB was independently associated with the patient developing 
severe ADRs; p=0.009. The median CD4 count in HIV-infected persons was 
204 (range 13 – 893) cells/mm3. The drugs used in the treatment regimens 
































 Grade: 0-2 
none/mild/moderate 





/death adverse drug 






     male 









     mixed origin 









     infected 









     yes 








Number of previous sensitive 
TB episodes (IQR) 
1(1-2) 1(1-2) 0.033 
Previous  MDR-TB episodes 
     yes 








Previous MDR-TB episodes 
(IQR) 
1(1-1) 1(1-2) 0.467 
Number of drugs in the 





    current 
    non 
    previously 
 
37(42)  







Weight at diagnosis of XDR-TB 
(IQR) 
48(44-59) 48(36-59) 0.626 
Age at diagnosis of XDR-TB 
(range in years) 
31.0(26.4-42.0) 36.8(25.0-46.2) 0.892 
Died 
     yes 










     yes 
     no 
 
             24(27.3%) 







Table 6.2    Socio-demographic and clinical characteristics of 115 patients who 















6.3.2     Frequency and severity of ADRs 
161 ADRs were experienced by 67/115 (58%) patients (Figure 1; upper panel). 
When the results were stratified by the number of patients:  17/67 (25%) patients 
required no intervention; 23/67 (34%) required modification of treatment, the 
offending drug was discontinued in 27/67 (40%) of patients; reactions were life *                                                                                                                                   
threatening in 2/67(3.0%), and 6/67(9.0%) died. When the results were stratified by 
ADRs (Figure 1; lower panel): in 58/161 (36%) instances an ADR was described but 
there was no intervention; 69/161 (43%) required modification of treatment in                                                                                                                                                                                                                                                                                                         
either the dose or frequency of the drug being taken, or, the prescription of an 
additional drug to treat the adverse event; the offending drug was withdrawn in 
34/161 (21%); the ADR was life threatening in 2/161 (1.2%) instances (both ADRs 
were due to renal failure), and death was associated with 6/161 (4%) of ADRs. All 6 
deaths were related to capreomycin (hypokalaemia in 1 patient and renal failure in 
5 others), and these patients died at a median of 14 days (range of 9-73 days) after 
starting capreomycin therapy. There was no association between the severity of 
ADR and frequency and duration with which the drug was used, or, the resistance 
















Treatment regimen characteristics: 
duration of treatment — months (IQR)          7.3 (3.12-12.6) 
duration of treatment with injectable agents -  months (IQR)                       4.4 (1.6-7.3) 
number of drugs in regimens among all available agents – median (IQR)                           7 (6-8) 
   Drug 
 
Number of patients who 
received a drug (%) 
Duration of treatment in 
months 
Median in months (range) 
Number of resistant isolates/ 





















Ethambutol 27(58.7) 19(41.3) 7.3(4.2-12.1) 8.7(2.4-12.1) 53/84(63) 9/27(33.3) 
Pyrazinamide 56(70) 24(30) 7.3(3,4-10.9) 9.6(2.9-11.1) Not Tested  Not Tested 
Amikacin 3(100) - 4.2(0.03-5.8) - 3/3(100)  Not Tested 
Capreomycin 78(75) 26(25) 7.4(3.1-12.4) 10.1(3.8-13.7) 13/27(48) 9/15(60)* 
Kanamycin 4(100) - 13.4(4.8-15.5) - 46/47(98) 4/4(100) 
Moxifloxacin 2(100) - 4.6(1.9-2.3) -  Not Tested Not Tested  
Ofloxacin 23(79.3) 6(20.7) 6.5(3.0-12) 8(8.0-12.0) 88/88(100) 27/27(100) 
Terizidone 80(76.2) 25(23.8) 6.8(3.4-12) 10(3.5-13.6)  Not Tested  Not Tested 
Ethionamide 45(68.2) 21(31.8) 7.6(3.5-11.8) 10(2.1-13.6) 44/85(52) 4/27(15) 
PAS 77(76.2) 24(23.8) 7.6(3.5-12.5) 10.1(3.3-13.9) Not Tested Not Tested 
Amoxicillin–
clavulanate 
46(70.8) 19(29.2) 6(2.2-11.1) 10.394.8-14) Not Tested  Not Tested 
Clarithromycin 57(77) 23(23) 7.4(3.1-13.9) 10.7(4.6-14.3)  Not Tested  Not Tested 
Clofazimine 25(89.3) 3(10.7) 8.7(4.4-14.2) 13.6(2.8-17.1)  Not Tested  Not Tested 
Dapsone 27(75)  9(25) 7.3(3-14.4) 5.8(3-11.9) Not Tested Not Tested 
Azithromycin 10(91)  1(9) 6.7(2.8-12.3) -  Not Tested Not Tested 
 
Table 6.3     Individualised regimens prescribed for 115 Patients with XDR-TB 

















Figure 6.2  
Kaplan-Meier probabilities of XDR-TB culture-conversion in: (A) The whole cohort of 
patients who experienced ADRs stratified by severity score i.e. none or mild to moderate 
(grade 0, 1 and 2), and severe (grade 3 to 5); (B) HIV-infected patients whom experienced 
ADRs stratified by stratified by severity score; (C) HIV-uninfected patients who experienced 
ADRs stratified by stratified by severity score, and  Kaplan-Meier probabilities of death: (D) 
The whole cohort of patients from the date of treatment-initiation, (E) HIV-infected 
patients who experienced ADRs stratified by severity score, and (F)  HIV-uninfected 




















6.3.3     Outcomes 
Culture conversion occurred in 26/115 (22.6%) of patients.  Patients with grade 3-5 
ADRs had a lower sputum culture conversion rate compared with those with grade 
0-2 ADRs [2/27(7.4%) vs. 24/88(27.3%); p=0.02; Figure 2A]. In the whole cohort the 
hazard ratio for ADR as a risk factor for culture conversion was 0.22 (0.05-0.95); p = 
0.04. There were no other significant variables associated with culture conversion. 
 
In contrast to HIV-uninfected patients (Figure 2C], HIV-infected patients (Figure 2B) 
with severe ADRs (grade 3-5) had a significantly lower sputum culture conversion 
rate than those with grade 0-2 ADRs [0/15 (0%) vs. 10/33 (30.3%), p=0.02].  
 
Of the 115 patients in the cohort, 30(26.1%) died. Overall, those who survived 
experienced fewer ADRs than those who died [48/67 (71.6%) vs. 19/67 (28.3%); p= 
0.01] and patients with grade 3-5 ADRs had a higher death rate compared with 
those with grade 0-2 ADRs [13/27(48.1%) vs. 17/88(19.3%); p=0.003; Figure 2D]. 
However, when risk factors for death were analysed by multivariate analysis in the 
whole cohort only culture conversion and previous MDR-TB (but not ADR) were 
independently associated with death (Table 3).  
 
In HIV-infected patients mortality rates were higher in those with grade 3-5 (severe) 
ADRs compared to those with grade 0-2 ADRs [7/15 (46.7%) vs. 8/33 (24.2%); 















severe ADRs had a higher death rate compared to those without severe ADRs 
[6/12(50.0%) vs. 9/55(16.4%); p=0.012; Figure 2F].  Of the 13 all-cause deaths 
occurring in the severe ADR group 6 were due to an ADR itself (5 due to renal 
failure and 1 due to hypokalemia - all ascribable to capreomycin). These patients 
were not terminally or critically ill and there was a clear temporal relationship 
between the initiation of the drug and the patient’s death.  Five out of the 6 
patients who died were HIV-infected. 
 
25/115 (21.7%) of patients defaulted from the inpatient facilities. There was no 
difference in the proportion of patients with severe ADR in those that defaulted 


























Univariate analysis Multivariate analysis 
Hazard Ratio (95%CI) P-value Hazard Ratio (95%CI) P-value 
Adverse drug reaction     
           Grade 3-5 2.4(1.1-5.0) 0.02 1.4 (0.7-3.1) 0.35 
           Grade 0-2             1              1  
Previous MDR TB     
           Yes 3.3(1.3-8.0) 0.01 2.9 (1.2-7.4) 0.02 
           No              1              1  
6 month culture-
conversion 
    
           Yes 0.1(0.01-0.6) 0.02 0.1 (0.01-0.8) 0.03 
           No               1              1  
 
Table 6.4 Univariate and multivariate analysis of factors associated with mortality in 
115 patients with XDR-TB 
 
21.7% (25/115) of patients defaulted from the inpatient facilities. The 
proportion of patients who experienced an ADR was no different in those 
who defaulted compared to those who did not 40% (10/25) vs.  60% (15/25), 
p=0.33.  However, default was more likely in those that had a severe ADR 
compared to those who did not [27/34 (79.4%) vs. 7/34 (20.6%); p=0.003]. 
 
















 6.3.4     ADRs in HIV-infected patients 
Outcome-independent data in HIV-infected patients 
The number of persons with ADRs, the number of total ADRs per person, and the 
number of severe ADRs was not significantly different in HIV-infected versus 
uninfected persons [29/48 (60.4%) vs. 38/67 (58%); p=0.26)] vs. [2.37 ADRs per 
person vs. 2.42 ADRs per person] vs.  [20/69(29.4%) vs. 14/92(15%); p= 0.31], 
respectively. Thus, the type, frequency and severity of the number of ADRs was 
similar in HIV-infected and uninfected patients. However, those who died of an ADR 
were more likely to be HIV-infected than HIV un-infected [5/6(83.3%) vs. 
1/6(16.7%), p=0.01)].  
 
34/48 (71%) HIV-infected patients were on HAART (highly active anti-retroviral 
therapy) but this did not impact on the frequency of ADRs and was generally well 
tolerated. 23/34 (68%) of patients were on a combination of lamivudine (3TC), 
stavudine (D4T) and efavirenz. The specific role of overlapping toxicities between 
HAART and anti-TB drugs could not be evaluated but the number of patients 
experiencing an ADR were significantly different in those taking HAART compared 
to HIV un-infected patients [29/34(85%) vs.   38/67(56.7%) p=0.008]. However, the 
number of patients experiencing a severe ADR were not significantly different in 
those taking HAART compared to HIV un-infected patients [11/34(32.3%) vs. 
















6.3.5     Drug-specific adverse events 
Of the total number of drugs stopped (n=34) capreomycin (Capstat; Pharmacare 
Johannesburg) was the most common drug withdrawn in 15/34 (44.1%) of cases, 
followed by PAS in 8/34 (23.5%) of cases, and ethionamide 7/34 (20.6%) of cases 
(Table 4). The withdrawal of capreomycin due to an ADR occurred at a median of 73 
days range (9-485) days after initiation of therapy. 
 
The most common reactions causing grade 3-5 ADRs were vomiting (29% of severe 
ADRs) and renal failure (21%). Some patients experienced multiple ADRs. These 
were frequently clustered in the gastro-intestinal subgroup. Thus, of those who had 
diarrhoea 15/22 (68.2%) also experienced nausea and vomiting, and 10/22 (45%) 
nausea and vomiting together with abdominal pain and dyspepsia. ADR clustering 
was also evident in the neurological category (overlapping symptoms of headaches, 
dizziness, generalised aches and pains etc). 
For each of the  18 drugs used in the XDR-TB treatment regimens there was no 
relationship between the severity of ADR and the number of patients who received 
each drug , total duration of treatment (months), and the proportion of resistant 

















6.3.6     ADRs stratified by Mycobacterium tuberculosis strain type 
Of the 115 patients with XDR-TB, isolates were available for genotyping in 53 of the 
patients from the Western Cape. Significantly more patients had a Beijing 
compared to a non-Beijing strain [81% (43) vs. 18.8% (10); p=0.0001]. The severity 







 *P= 0.03 (severe vs. mild to moderate ADRs) 
 **p=0.0001 (total Beijing versus non-Beijing) 
 
Table 6.4     Effect of TB strain type on ADRs stratified by Beijing strains and non-
Beijing strains 
 




Severity of ADR ADRs 0-2 ADRs 3-5 ADRs 0-2 ADRs 3-5 
HIV-infected 9/14 (64.3) 5/14 (35.7) 1/3 (33.3) 2/3 (66.7) 
HIV-uninfected 20/29 (69.0) 9/29(31.0) 5/7 (71.4) 2/7 (28.6) 
Sub-totals 29/43 (67.4) 14/43 (32.6)* 6/10 (60) 4/10 (40) 
 















6.4    Discussion 
This is the first comprehensive report of ADRs and their impact on outcomes in a 
large cohort of patients with XDR-TB. Our key findings were that: (i) the frequency 
of ADRs with XDR-TB treatment regimens is high (~60%), and in 20% of cases the 
ADR was associated with interruption therapy or fatal consequences; (ii) HIV-
infected patients with XDR-TB were more likely to die from a severe ADR and thus 
greater vigilance is required in this group; (iii) those with severe ADRs have poorer 
culture conversion but not higher mortality thus underscoring the need for careful 
treatment monitoring for early detection of ADRs, and (iv) capreomycin was the 
most common cause of drug withdrawal (44% of all withdrawals) and thus careful 
monitoring of this drug is mandatory. 
             
A fundamental finding of this study is that XDR-TB patients with severe ADRs had 
poorer culture-conversion outcomes This is in keeping with the findings of 
O’Donnell et al (O Donnell  et al., 2009) but in contrast to patients with MDR-TB 
from Turkey (Torun et al., 2005) and Russia where ADRs were common (~ 70% of 
patients) but were not associated with unfavourable outcomes (Shin et al., 2007). 
Thus, in contrast to MDR-TB, in XDR-TB patients the consequences of ADR-
associated interruption of individual drugs impacts on culture-conversion 

















The high capreomycin toxicity seen in our study (almost half of all drug withdrawals 
due to an ADR) is in keeping with the findings of a Peruvian study where 31% of 115 
MDR-TB patients had hypokalaemia, which was independently associated with the 
administration of capreomycin (Shin et al., 2007). Based on our findings we suggest 
weekly checks of renal function and electrolytes in the 1st 4 weeks of therapy, and 
then every 2 weeks for the next two months, and monthly thereafter. Active 
monitoring for ADRs, correct dosing by body weight, correction of dehydration, and 
regular monitoring of renal function and electrolytes is required particularly in 
those with risk factors (hypertension, diabetes, HIV-associated nephropathy, 
vomiting and diarrhoea, dehydration, electrolyte abnormalities, diuretic usage, 
alcohol abuse, and use of potentially nephrotoxic drugs such as tenofovir, 
cotrimoxazole etc). This has implications for the out-patient management of XDR-
TB, which is currently being rolled out in high burden settings due to the sheer 
burden of cases that have overwhelmed designated facilities (Mitnick et al., 2008). 
Our data inform on resource allocation by national TB programmes in high burden 
settings that will need to take into account provision of monitoring and laboratory 
infrastructure when planning decentralised and nurse-led services for drug-
resistant TB. Given the associated poorer outcomes in XDR-TB patients with ADRs, 
health care workers should be educated about the recognition of ADRs, and 
patients should be followed up more closely and be offered appropriate counselling 
to ensure drug adherence. Thus, our recommendations are easily implementable 
and do not detract from providing decentralised MDR treatment services in 















             
Nausea and vomiting, in keeping with the findings of Shin et al. (Shin et al., 2007), 
was the most common reason for suspension of drug therapy (in any severity 
category) and needs to be managed with patient counselling, anti-emetics, and/or 
splitting of the dose to improve tolerability. ADRs although frequent were not more 
common in HIV-infected patients unlike observations that we (Marks et al., 2009) 
and others (Yee) have documented in patients with drug-susceptible TB. The 
reasons for this are unclear but could reflect poorer absorption of second line drugs 
and hence lower serum levels, or, ascertainment bias as HIV-infected patients may 
have died prior to diagnosis. Nevertheless, HIV-infected patients were more likely 
to die from severe ADRs and increased vigilance and correct dosing by body weight 
is required in this group.  
             
The frequency of ADRs in this study (~60%) are similar to those that evaluated ADRs 
to second line drugs in the context of XDR-TB (58%)(O Donnell  et al., 2009) and 
MDR-TB  (73.3% in Tomsk, Russia (Shin et al., 2007), 69,2% in Istanbul Turkey (Torun 
et al., 2005)and 79% in Latvia (Bloss et al., 2010 )but twice that of ADRs to first line 
drugs in those with drug-susceptible TB (Migliori et al., 2008). Suspension of any 
agent (16% in our study) occurred at a similar frequently compared to a Peruvian 
study in patients with MDR-TB (14%) (Furin et al., 2001) but less frequently than in 
a large multi-centric study in patients with MDR-TB (30%) (Nathanson et al., 2004), 
in Turkish patients with MDR-TB (55%) (Torun et al., 2005), and in patients with 















 We found no significant association between strain phenotype and the frequency 
or severity of ADRs. This may reflect a true lack of association or type 2 error given 
the small numbers of isolates that were accessible for genotyping. Recent data 
suggest that DR-TB strains have in addition to resistance conferring mutations 
hundreds of compensatory mutations that may alter the structure and hence 
antigenic properties of the organism (Desouza et al.).  This may impact host 
immune profiles and hence interaction with drug compounds. Further and larger 
studies are required to clarify this issue.  
           
Similar to findings in earlier studies in drug-susceptible TB (Javadi et al., 2007); (Yee, 
2003, Marra F, 2007), there was the higher number of women experiencing ADRs. 
The reason for this remains unclear. Similar to the findings in the context of drug-
susceptible TB (Javadi et al., 2007), the higher rate of ADRs in those with prior MDR-
TB, may reflect prior sensitisation, higher drug levels in patients with a lower body 
weight, and the generally poorer health status in keeping with chronic disease.  
           
There are several limitations of our study. These include the retrospective study 
design, ascertainment bias due to data capture from medical notes, inability to 
calculate drug-specific ADR rates and ADR rates per person months of exposure, or 
to definitively delineate ADRs from disease-related morbidity in HIV-infected 
patients. However, this is difficult to calculate even in prospective studies because 
of the inability to ascribe a particular ADR to a specific drug in a multidrug regimen. 















clinicians who based assessments on their clinical judgement and temporal 
relationship to symptoms, signs, and laboratory data, and we only extracted 
variables that could be confidently ascertained. We were also reliant on the 
judgement and investigative evaluation of clinicians who ascribed renal failure to 
capreomycin rather than dehydration, vomiting and diarrhoea etc. Thus, our 
analysis may reflect this clinical bias. Survivor selection bias may have led to an 
underestimate of the true mortality in the HIV-infected sub-group whilst late 
detection and delayed management of ADRs could have contributed to mortality 
given that severe ADRs occurred on average about 2 months after mild to moderate 
ADRs. Only a prospective study will be able to address this hypothesis. Our findings 
are only generalisable to a resource-poor high HIV prevalence setting like South 
Africa where there is a high rate of prior MDR-TB and of concomitant substance 
abuse.  
 
In conclusion, the frequency of ADRs with XDR-TB treatment regimens is high and 
often severe. Those with severe ADRs have poorer treatment-related outcomes. 
Early detection and monitoring of ADRs is thus crucial, and XDR-TB patients with 
ADRs should be closely monitored for the remainder of their therapy. Assays to 
monitor serum levels of second line drugs and less toxic drugs are urgently needed. 
These data inform on the management and monitoring of patients being treated for 
XDR-TB, factors that impact on patient compliance, and the provision of resources 
within national TB programmes that seek to offer decentralised and nurse-led care 















Chapter 7 Discussion 
XDR-TB has now been identified in over 59 countries and, given recent changes in 
international travel and migration patterns, the threat is global. Treatment of XDR-
TB results in modest survival and treatment-related outcomes in intermediate and 
low burden settings (WHO, 2010). However, despite having the highest TB and 
TB/HIV caseload in the world, there have been scant data on M/XDR-TB from high 
burden settings in sub-saharan Africa. This is not due to absence of drug-resistant 
cases of TB but due to lack of data, which cannot be collected because of the 
absence of drug-testing facilities or the capacity to perform the required diagnostic 
studies. Thus, for economic and logistical reasons, routine drug susceptibility 
testing (DST) testing services are not available in high TB endemic countries, and 
any M/XDR-TB incidence and prevalence data from African countries may be a gross 
underestimate. Our work, recently published in the Lancet, indicates that XDR-TB 
inflicts a high mortality, causes chronic pulmonary disability, and diverts ~40% of 
TB-devoted resources away from existing treatment programmes. The key findings 
outlined in this thesis are: 
(i) Survival in HIV-infected patients is better than that previously 
reported by the KwaZulu-Natal outbreak study.  
(ii) HIV-infected XDR-TB patients treated with highly active anti-
retroviral therapy (HAART) had lower mortality than untreated 
patients. 
(iii) Moxifloxacin was an independent predictor of survival. 
(iv) Previous culture-proven MDR tuberculosis and high number of drugs 















(v) The outcome of management of patients with XDR tuberculosis in 
South Africa is poor, despite good adherence and availability of 
drugs. 
(vi) Diagnosis occurred more than two months after presentation 
because of the lack of rapid diagnostic testing facilities 
(vii) Side effects of TB drugs used in the management of XDR-TB patients 
may interfere with treatment completion. 
(viii) XDR-TB among health care workers is now an urgent issue and the 
magnitude of the problem, including implementation of infection 
control measures in health care facilities, needs to be defined. 
 
One of the key findings in our study, as discussed in chapter three, was the 11% 
(21/195) of patients who died before starting treatment, which indicated that the 
patients either, had late access to treatment or inappropriate delivery of health 
services. Our data emphasises the need to reduce delays in diagnosis and initiation 
of treatment through intensified case finding, {Basu, 2009 #201}, improved patient 
access, diagnostic reporting systems {Loveday, 2008 #1506;Storla, 2008 #1378}, and 
improvement in the rollout of rapid diagnostic tests for XDR tuberculosis as has 
been laid out in chapter three (Ling DI, 2008). Development of alternative methods 
that could be useful for detection of sputum-smear-negative tuberculosis are also 
urgently needed as well as validation of newly developed tests such as   the Hain SL, 
















The high capreomycin resistance, also highlighted in chapter three, is a cause for 
concern since this antibiotic is the mainstay of regimens for the treatment of XDR-
TB globally, and has not been widely used in South Africa previously. The reasons 
for this high resistance are not known, but it might partly indicate the unreliability 
of capreomycin susceptibility testing, or the potentially high cross-resistance with 
aminoglycosides like kanamycin and further work in this area needs to be 
undertaken {Jugheli, 2009 #1610;Via, 2010 #1366}. 
 
With our findings, in Chapter 3, as well as those from other  studies looking at MDR 
tuberculosis {Leimane, 2005 #1517;Mitnick, 2008 #1497}, we suggest that patients 
with a weight of less than 50 kg should be given nutritional supplementation, 
intensive follow-up, and a bolstered regimen (Podewils et al., 2011). These 
recommendations, which also have importance for the design of treatment 
programmes, need to be prospectively validated 
 
Also covered in chapter three is a section on transmission dynamics. The KwaZulu-
Natal strain showed different pathogenic properties due to its high capacity to 
cause reinfection, and clonal expansion through transmission, compared with the 
findings in the Western Cape, where we know that resistance was mostly acquired 
(81%) (Andrews et al., 2007){Ioerger`, 2009 `#1514}. The 19% primary transmission 
we have reported on is of growing concern, and the scenario of infectious patients 
awaiting sputum results, or a bed in the XDR-TB facility or alternatively when the 
patient is sent back to the community once treatment has failed is a reality. 















administrative measures for a rapid turnaround of sputum results and earlier 
treatment initiation need to be in place. The high incidence of M/XDR-TB in HCW’s 
as described by us {O’Donnell, 2010 #1596} highlights that administrative measures, 
in particular the importance of appropriate infection control, need to be rolled out , 
especially for HCW’s who are immune-compromised.  
 
In chapter four we address the low conversion rates (19%) which were not, 
however, affected by HIV status, possibly because the HIV-infected patients were 
dying before diagnosis, or treatment initiation. Of the patients who converted, 85% 
had done so by month nine, with only 6% (2/33) converting thereafter. This has 
implications for TB programmes in defining XDR-TB treatment failure. The average 
time from sputum acquisition to treatment start was 75 days (see chapter 3) which 
also contributes to the low conversion rates, and once again highlights the need for 
roll out of rapid diagnostics. The low conversion rates also underscore the necessity 
and urgency of developing new drugs for treatment of XDR-TB. Patients, whom 
reconvert back to positive or never convert in the first place, thus defined as a 
treatment failure, are discharged back into the community where transmission of 
XDR-TB continues. The poor conversion rates also underscore the need to urgently 
develop and prospectively validate new diagnostic tests, treatment and prevention 
interventions for XDR-TB.  Other preventative measures are described in the last 
paragraph. The next step then was for us to look at our mortality findings. 
 
Looking at the available data for XDR tuberculosis from Africa we saw that this 















patients with both diseases was poor with a high 30-day mortality rate {Ghandi, 
2006 #177;Gandhi, 2009 #90}. By contrast, we have shown in chapter 5, that 
substantial proportions (53%) of patients in our study   were HIV-negative. Survival 
in patients with HIV infection in our study cohort, from a wider South African 
setting, is substantially longer (50% died at 12 months vs. 83–100%  then those 
seen in KwaZulu-Natal {Ghandi, 2006 #1386;Gandhi, 2009 #90}. Although not small, 
this proportion is substantially better (Gandhi et al., 2009, Gandhi et al., 2010). The 
reasons are unclear, as elucidated in chapter 5, but might include patients 
presenting at different stages of their illness, the degree of immune-suppression, 
different drug-susceptibility profiles of isolates, lack of availability of capreomycin 
before 2006, nutritional status, and local differences in strain virulence. XDR 
tuberculosis in South Africa is therefore not predominantly associated with HIV 
infection or more than 80% mortality within a few weeks as perceived from studies 
done in KwaZulu-Natal in 2006 and 2009 {Ghandi, 2006 #177;Gandhi, 2009 #90}.  
Although the numbers of deaths in our study were high, we noted no difference in 
treatment outcomes (mortality and culture-conversion status) when comparing 
patients who were HIV-positive with those who were HIV-negative. This finding is 
important for the design of policy guidelines and programmes, and de-stigmatises 
XDR-TB in HIV-infected persons. 
 
These poor outcomes draw attention to the need to urgently develop and 
prospectively validate new interventions for XDR tuberculosis (Rook and 
















Independent of HIV status, possible reasons for the poorer survival in our cohort of 
patients as cited in chapters 4 (conversion) and 5 (mortality), include the long 
duration of drug-resistant and drug-susceptible tuberculosis before initiation of 
treatment for XDR tuberculosis; delays in initiation of such treatment; malnutrition; 
co-exposures such as smoking, alcohol, and illicit drug use; different M. tuberculosis 
strains (their pathogenic characteristics and resistance patterns); lack of treatment 
with moxifloxacin and low weight (<50kg). These poor outcomes underscore the 
need to urgently develop and prospectively validate new diagnostic, treatment and 
prevention interventions for XDR-TB.   
 
The outcome data as discussed in chapters 4 and 5, (conversion, and mortality) and 
the high proportion of acquired resistance to second-line drugs in this study and 
nationally as addressed in chapter 3 {Mlambo, 2008 #91;Pillay, 2007 #106}, suggest 
that the national tuberculosis control programmes needs to aggressively ensure 
treatment adherence with effective regimens to restrict the spread of resistance. 
This prevention of drug resistance can be achieved by programme strengthening to 
prevent system failures, {Padayatchi, 2008 #1595;Loveday, 2008 #1506}, 
integration of treatment for drug-resistant tuberculosis and HIV/AIDS, (Gandhi et 
al., 2009),  intensive counselling and follow-up, and surgery where it is  indicated 
and feasible.  
We also show, in Chapter 5 that highly active antiretroviral therapy, despite its 
overlapping toxicity and adverse drug effects with anti-tuberculosis drugs, and the 
high pill burden, substantially improves survival in patients with concomitant 















that highly active antiretroviral therapy should be used at an early stage, regardless 
of CD4 count, in patients with HIV infection and XDR tuberculosis. These findings 
are important for advocacy purposes because they support the notion that 
treatment for XDR tuberculosis in patients with HIV infection is not without hope, 
and thus counteracts the stigmatisation of this group of patients.  
 
Another very important finding also discussed in chapter 5 is that treatment with 
moxifloxacin was an independent predictor of survival in ofloxacin-resistant 
patients with XDR tuberculosis. Jacobson et al. in their meta analysis also found that 
moxifloxacin was a predictor of survival (Jacobson, 2010).  Evidence suggests that 
the incomplete cross-resistance within the quinolone class can be explained by 
differential drug-specific binding to DNA gyrase {Kam, 2006 #1512}. Unlike the 
cohort in Mitnick and colleagues’ study, (Mitnick et al., 2008) with 72% (34/47) 
patients ever treated with moxifloxacin, our programme does not provide this drug 
nationally. Prospective clinical and in-vitro studies are urgently needed to 
investigate how best to use newer generation fluoroquinolones for treatment of 
XDR-TB. Meanwhile, we recommend that, in the absence of specific results of drug-
susceptibility testing, moxifloxacin should be used in treatment regimens for XDR-
TB unless contraindicated. This is an extremely important finding because there are 
no new licensed drug options for XDR-TB in high-burden settings. 
 
Our data, as discussed in chapter 6, shows a high incidence (60%) of adverse events 
associated with drugs used for the treatment of XDR-TB and this was unaffected by 















mortality (chapter 5). In 40% of ADR’s treatment was modified and in 20% of cases 
the drug was discontinued, interrupting therapy, sometimes with fatal 
consequences. The most serious adverse effects were caused by capreomycin-
associated renal dysfunction, which can occur at any time during the course of 
treatment; thus monitoring of capreomycin-based regimens, even in resource-poor 
settings is mandatory. Capreomycin was the most common cause of drug 
withdrawal in 44% of patients, and was responsible for all deaths attributed to a 
severe ADR.  ADR’s need to be vigilantly monitored, and major global funders need 
to input sufficient resources so the epidemic doesn’t progress.  
 
Limitations (as set out in chapters 3-6) of our findings are due to the retrospective 
study design. We have tried to reduce bias by excluding patients with incomplete 
treatment and microbiological data, by excluding individuals who had culture 
converted before initiation of treatment for XDR-TB, or whose sputum status was 
unknown at treatment initiation, by crosschecking patients against clinical and 
laboratory databases, and by using methods to ensure data integrity. The use of 
different data collectors at the various sites could have added further bias. 
Furthermore, the patients who died are included in the study but were excluded 
from the specific analysis of treatment-related outcomes as they did not receive 
therapy. HIV-infected and uninfected patients may have died due to failure to treat 
(before they sought diagnosis, or diagnosis was late or inappropriate, or due to the 

















In summary, while survival is better than previously reported, prognosis is still poor. 
HIV-infected patients treated with HAART had a lower mortality and moxifloxacin 
was an independent predictor of survival. Prior culture-proven MDR-TB and 
increasing number of drugs used in a regimen were predictors of survival and 
culture-conversion. The significant mortality rates reported brings to light the 
question of variations in M.tuberculosis strain virulence and their transmission 
patterns. Diagnosis occurs more than two months after presentation, and 
treatment initiation some one to two months thereafter. Adverse side-effects of TB 
drugs used in the management of XDR-TB patients are high, often severe and can 
lead to disability and even death. High XDR-TB rates among health care workers are 
a growing concern. These data call for: (i) The design, development and prospective 
validation of policy guidelines and programmes especially in the following areas: (ii) 
management policies, (iii) tools to intensify case finding, (iv) strategies to improve 
patient access to treatment, (v) new treatment and prevention interventions (vi) 
intensive counselling and follow-up, training and advocacy for HCW’s, (vii) 
appropriate infection control measures in health care facilities and  (viii) the 
exploration and roll out of community based, nurse initiated treatment models. (ix) 
Improvement in the rollout of rapid diagnostic tests as well as diagnostic reporting 
systems and rapid testing facilities, (x) development of alternative methods that 
could be useful for detection of sputum-smear-negative tuberculosis, (xi) validation 
and implementation of newly developed tests such as the Hain SL, and GeneXpert 
tests. (xii) Patients with a weight (<50kg) should be given nutritional 















of new licensed drug options for XDR-TB, (xiv) in the absence of specific results of 
drug-susceptibility testing moxifloxacin should be used in treatment regimens for 
XDR-TB, (xv) and monitoring of capreomycin-based regimens. (xvi) Surgery where it 
is indicated and feasible. (xvii) Major global funders need to provide sufficient 
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